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Glioblastoma (GBM) is the most common and aggressive primary human brain tumor 
associated with very poor prognosis and survival (Stupp and Hegi, 2019). Despite ongoing 
research, the outlook on GBM remains quite disappointing with a median survival of ~15 
months and 5-year survival rate less than 5%. The fact that treatment and prognosis have 
remained unchanged for fifteen years leads to the realization that there are major 
challenges that we have not been able to overcome. Challenges are fundamentally 
represented by (i) the tumor itself, (ii) the anatomic localization, and in particular the 
presence of the Blood Brain Barrier (BBB), and (iii) the toxicity of current treatments.  
Nanotechnology can be instrumental for all of these issues. The ultimate goal of this 
project is the development of multi-task targeted, drug-loaded Nanovectors (NVs) able to 
cross the BBB and  target GBM, release chemotherapeutics and induce tumor cell death 
and disease regression. 
Liposome (LIPs) incapsulating Doxorubicin (DOXO) and functionalized with a peptide 
derived from the ApoE lipoprotein (mApoE), mApoE-DOXO-LIPs, demonstrated the 
ability to cross BBB and target the Glioblastoma Stem-like cells (GSCs) both in vitro and, 
especially, in vivo reducing the tumor growth in PDX mice cotreated with radiation (2Gy 
dose). Moreover, the histological analysis demonstrated that 2Gy/mApoE-DOXO-LIPs 
treatment induced apoptosis in tumor cells preventing side effects on healthy brain 
parenchyma, reducing the toxicity of the drug. Interestingly, morphological and 
histological analysis on Iba1+ cells suggested that GSCs apoptosis could induce Immune 
cell death (ICD) activation with in turn could activate the immune system against GBM. 
However, LIPs treatment still induced systemic toxicity in treated mice, probably due to 
the high accumulation of the NVs in the liver (approximately 40% of injected LIPs), 
causing a body weight loss of approximately 12%. To reduce the LIPs side effect different 
polymeric NVs were tested. Poly(lactic-co-glycol acid) (PLGA) and poly(ε-caprolactone) 
(PCL) NVs functionalized with a MMP2 Activatable Low Molecular Weight Protamine 
(ALMWP) were chosen to reduce NVs side toxicity. While linear PLGA NVs wasn’t 
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effective due to their fast drug release, star shaped PCL NVs (ALMWP-DOXO-PCLs) 
were able to induce in vitro GSCs death at a extremely low DOXO concentration 
(approximately 10 time lower than LIPs) without affecting healthy cells like the 
endothelial cells. 
The work of this thesis demonstrates that drug-loaded targeted nanovectors can function as 
a delivery strategy to specifically and effectively drive chemotherapeutics into GBM tumor 
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1. CNS tumor 
Tumors of the central nervous system (CNS) comprise a heterogeneous group of 
neoplasms that vary in location, age at onset, histologic features, tendency for progression 
and migration, and response to therapy (Louis et al., 2007).
 
These tumors exhibit a wide 
spectrum of histologic subtypes reflecting their potential cell of origin, local 
microenvironments and clinical outcome (Gutmann et al., 2006).  
Historically, CNS tumors were classified mainly based on histogenesis, according to their 
similarities with the putative cells of origin and their levels of differentiation (Louis et al., 
2016). The largest group of primary brain tumors (42% of total events) is represented by 
gliomas, that have many histologic features in common with glial cells (astrocytes, 
oligodendrocytes and ependymal cells) (Louis et al., 2007). Other brain tumors arise from 
ectodermal structures related to the brain (meningioma), from lymphocytes (CNS 
lymphoma), or from precursor neuronal elements (neuroblastoma, medulloblastoma), germ 
cells (germinoma, craniopharyngioma, teratoma), or endocrine elements (pituitary 
adenoma). 




all other neuroepithelial tumors
tumor of the meninges
tumor of cranial and paraspinal nerves
lymphomas and hematopoietic neoplasm
all others
In 2016 the World Health Organization (WHO) updated the classification by combining 
histopathology with the genetic molecular characteristics of the CNS tumor. Nowadays, 
histology, WHO grade (I to IV, with IV grade representing the most malignant behavior) 
assigned based on the presence or absence of anapestic features, and molecular profile are 
considered as different layer that define the final integrated diagnosis of the CNS tumor 
(Fig. 2) (Weller et al., 2015). 
Fig. 2: Layered diagnosis of CNS tumors. Integrated diagnosis (layer 4) comes last, when layers 1–3 are 
defined. WHO grading criteria (layer 3) and relevant molecular information (layer ) are separately defined for different 
histologic tumor types. Adapted from Johnson et a., 2016. 
Among all the molecular alteration that accord in CNS tumor two of them were selected 
for their pivotal biological and clinical relevance in diagnosis determination: 
1. Isocotrate dehydrogenase 1 (IDH1) mutation: the wild-type (wt) form of these gene 
confers a worse prognosis respect the mutated (Hartmann et al., 2010) 
2. Translocation of the p-arm chromosome 1 with the q-arm of chromosome 19 (1p/19q 
codeletion): improved prognosis and response to chemotherapy (Weller et al., 2013) 
The 2016 classification underline the importance of the molecular “layer” and prompted a 
lot of new discover on this aspect. Therefore, the Consortium to Inform Molecular and 
Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) was created to 
disseminate the updates and to direct the future WHO classification. Recently, a new WHO 













2021. In this new classification the molecular alterations will be the main elements that 
will drive to the final diagnosis, definitively overturning the importance of the paradigma 
histology/molecular features. 
1.1 Glioblastoma 
GBM (designated WHO grade IV) is the most common malignant primary brain neoplasm 
in the adults, accounting for approximately 20% of all intracranial tumors and more than 
80% of gliomas of the cerebral hemispheres (Hanif et al., 2017). GBM incidence is 5-7 
cases per 100 000 people per year worldwide (Thakkar et al., 2014), with a peak incidence 
between 55 and 60 (Hanif et al., 2017) and a slightly higher prevalence in men compared 
to women, with a ratio of 1.6:1 (Davis., 2016). Until now, GBM doesn’t have an etiology 
correlation with typical environmental factors such as smoking, diet or cell phone use and 
the only known risk factor is the exposure to ionizing radiation (Alexander and Cloughesy, 
2017; Davis., 2016).  
GBM represents one of the deadliest tumors with a 5-year survival rate of <10%, and a 
mortality rate close to 100% (Taylor et al., 2019). Its unfavorable prognosis is mainly due 
to its high propensity for tumor recurrence that inevitably occurs after 6-9 months after 
diagnosis. 
1.1.1 Histopathology 
Generally, GBM arise in the supratentorial region. Only 5% of the cases are located in the 
cerebellum, brainstem and spinal cord (Nakada et al., 2011). Usually, GBM appear as a 
single and large lesion with irregular shape (Nelson and Cha., 2003) composed by several 
regions that differ for their histological appearance (Smith and Ironside, 2007; Agnihotri et 
al., 2013): 
1. Necrotic area 
2. Multifocal hemorrhage area 
3. Cystic and gelatinous area 
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Histologically, GBM is composed by either a pleomorphic small cell population poorly 
differentiate or large multinucleate cells with multifocal necrosis and the presence of 
pseudopalisanding nuclei (Nelson and Cha, 2003; Frosch, 2013). Another characteristic of 
GBM is the presence of vascular endothelial cell proliferation (Smith and Ironside, 2007; 
Agnihotri et al., 2013) (Fig. 3). 
 
Fig. 3: GBM histology. Foci of necrosis with pseudopalisading of malignant nuclei and endothelial cell proliferation. 
1.1.2 Molecular pathology 
GBM represents one of the most comprehensively genetically characterized cancer types, 
leading to recognition of groups defined by transcription profile. Multi-dimensional and 
comprehensive characterization of more than 500 GBM sample have demonstrate how 
each GBM represents an unmatched set of genomic alteration, marker expression and 
pathway activation (Brennan et al., 2013). 
According to the 2016 WHO classification, GBM is now subdivided into two types on the 
basis of the presence or absence of IDH mutation (Yan et al., 2009): wt IDH1 is present 
tumor diagnosed as GBM (primary GBM) while mutated IDH1 is generally associated to 
GBM derived from lower grade glioma (secondary GBM). Harbouring IDH mutation has 
been found to confer an increased survival compared to wild-type GBMs. Primary and 
secondary GBM have different pathogenesis that confer them a specific molecular pattern 
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(Ohgaki and Kleihues, 2007; Agnihotri et al., 2013; Ohgaki and Kleihues, 2013; Liu et al., 
2012; Cloughesy et al., 2014): 
• Primary GBM: Epidermal Growth Factor Receptor (EGFR) mutation, 
overespression of Mouse Double Minute 2 (MDM2), deletion of p16 and 
loss of heterozygosity of chromosome 10q holding phosphatase and 
tensing homologue (PTEN) and mutation in the promoter of TERT 
• Secondary GBM: overexpression of platelet derived growth factor a and 
platelet derived growth factor receptor alpha (PDGFA/PDGFRα), 
retinoblastoma (RB), loss of heterozygosity of 19q and mutation in 
IDH1/2, TP53 and ATRX. 
In addition to IDH status, other two molecular features are routinely used in the clinic for 
GBM prognosis (Fig. 4): 
1. O-6-methylguanine-DNA methyltransferase promoter methylation 
(MGMT) - MGMT function as a dealkylating agent (Lee, 2016). The 
interest in this gene has increased considerably since the publication that 
GBM patients with methylated, and consequently inhibited, MGMT 
promoter had more prolonged survival when treated with temozolomide 
(TMZ) than patients with unmethylated MGMT promoter (Weller et al., 
2015). 
2. 1p/19q co-deletion - One study demonstrated that the presence of 
complete or partial co-deletion of 1p and 19q conferred a significantly 
increased response to chemotherapy, and prolonged disease-free survival 
time, compared to tumors of only one or the other chromosomal arm, 
regardless of histologic subtype (MnNamara et al., 2017). Due to the 
significant clinical implications for the presence of this gene, 1p/19q co-
deletion testing should be performed on all glial tumors, included GBM, 
with or without oligodendroglial features, since a small percentage (5%) 
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of morphological astrocytomas are with 1p/19q co-deletion, which may 
confer a slightly better prognosis for the patients (Shan et al., 2019). 
In 2010, for the first time, Verhaak et al. (Verhaak et al., 2010) classified GBM subtypes 
based on specific gene expression signature. They identify four different subclasses 
reminiscent of distinct neural cell of origin, associated with different incidence and clinical 
outcome (Fig. 4): 
1. Proneural (PN) highly enriched in oligodendrocyte signature; 
2. Classical expressing an astrocytic signature; 
3. Neural associated with oligodendrocytic and astrocytic but also enriched 
in neurons genes; 
4. Mesenchymal (MES) associated with an astroglial signature. 
Fig. 4: GBM subtypes and their incidence and malignancy. Adapted from Fedele et al., 2019.  
Since then, many studies enforced and amplify this classification, defining a specific set of 
genes for each signature. This allow to established the presence of two main GBM subset 
(PN and MES) and an intermediated one (Classical) (Bath et al., 2013; Halliday et al., 
2014; Moreno et al., 2017; Rooj et al., 2017; Minata et al., 2019) since the Neural subset 
probably arise from the neuronal tissue that surround GBM margins (Wang et al., 2017) 






Worse prognosis than Neural
Neural 
Intermediated correlation with OS
Proneural 
Good prognosis
hypoxic, necrotic, inflammatory, and multitherapy-resistant features than other 
transcriptional subtypes (Kim et al., 2021). 
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2. Clinical features and therapy 
GBM patients present a short clinical history in more the 50% of the cases (3-6 months) 
while could be spans over years for the GBM developed from low-grade tumor (secondary 
GBM) (Clarke, 2005; Salah Uddin and Jarmi, 2015). Symptoms could arise suddenly and 
often can be confused with symptoms of other disease (like stroke). The more frequent 
symptoms are slowly progressive neurologic deficit, usually motor weakness (10 to 40%), 
headache (50 to 60%), headaches, nausea, vomiting and cognitive impairment seizures (20 
to 50%). These sing or symptoms are generated by three different mechanism (Clarke, 
2005; Salah Uddin and Jarmi, 2015): 
1. Brain tissue damage and necrosis provoked by the tumor generate specific deficit 
based on the region where GBM is located; 
2. Increased intracranial pressure due to the increase of the tumor mass and the edema 
surrounding the tumor. A typical symptoms caused by the increase pressure is 
headache; 
3. Brain area where GBM arise is the main cause of the presence of seizure. 
Despite the enormous effort oft he international community, GBM remains an incurable 
disease, with a median survival of just 15 months. The most consistently reported and best-
established prognostic factors include (Xavier-Magalhães et al., 2013): 
1. Age of the patient 
2. Tumor location 
3. Who grade  
4. Performance status of the patient  
5. Extent of surgical resection 
Recently molecular stratification with biomarkers (IDH1, MGMT status, 1p/19q) have 
been recognized as predictive of patient response and outcome, proving crucial in 
rationalizing treatment decisions in addition to the classical histological prognostic factors. 
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Currently, the most efficient and standardly used protocol for GBM treatment is the one 
proposed in 2005 by Stupp et al. (Stupp et al., 2005), basically composed of two steps: 
1. Surgery. Surgery is the principal component of GBM standard care. 
Tumor mass removal can lead to many benefits including reduction of 
tumor burden, reduce  seizure, limit and abolish the neurological deficit. 
Surgery carries also a  diagnostic roles since it provides tissue specimen 
for histologic and molecular diagnosis. Notably, during surgery it is also 
possible to introduce local therapeutic agent in order to improve the 
efficacy of the resection and quality of life (Newton et al., 2007) 
However, the high degree of GBM invasion often in eloquent areas makes 
extensive and complete resection impossible (Iacob and Dinca, 2009). 
Therefore, GBM recurrence occurs in 80% of the cases within 2-3 cm 
from the original tumor (Mrugala, 2013).  
2. Radiation and Chemotherapy. In order to kill the invading cells that 
have not been removed by the resection, surgery is followed by 
radiotherapy (RT) and chemotherapy with TMZ cotreatment. Different 
RT protocol tested (fractionated, brachytherapy or stereotactic 
radiosurgery) have shown to be effective against  GBM relapse improving 
life expectancy of patients (Hanif et al., 2017). However, some limitation 
and side effect are associated with RT. Among them are radio necrosis 
and permanent neuronal damage (Iacob and Dinca, 2009). Moreover, 
GBM react to RT with enhanced invasiveness and tumor cell radio 
resistance (Iacob and Dinca, 2009). 
As adjuvant of RT, TMZ is currently used as standard treatment of GBM 
patients (Reardon and Wen, 2006; Iacob end Dinca, 2009). TMZ is an 
alkylating agent. Its toxicity is related to the DNA methylation at the N7 
and O6 position on the guanine in replicating cells. The guanine 
methylation leads to DNA miss match repair failure and consequent cell 
death (Scott et al., 2011). However, likewise RT also TMZ have limitation 
and side effect, in particular hematologic toxicity (Chang et al., 2007). 
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Despite surgery and radio- chemotherapy, GBM inevitably recurs after 6-9 months from 
diagnosis and only approximately 3-30% of the patients are eligible for re-operation or re-
irradiation (Robin et al., 2017). Mostly, patients are treated with chemotherapy as second-
line treatment. Antiangiogenics, inhibitors of the epidermal growth factor receptor, 
nitrosoureas, and re-treatment with TMZ have been studied in the second line, but a 
standard therapy has not yet been established. In the last years, many attempts have done to 
develope new efficient therapy. The more promising admitted to clinical trials are based on 
(Mohtashami et al., 2020): 
1. Molecular signaling. In GBM context, many signal pathway are altered 
causing uncontrolled proliferation, neoangiogenesis, cell migration and 
differentiation (Preusser et al., 2015; Soukhtanloo et al., 2020). Many 
attempts have been done to developed tyrosine kinase inhibitor targeting 
specific pathway extremely important in GBM and in tumor in general. 
Among them are the pathways involving the Epidermal Growth Factor 
Receptor (EGFR), overexpressed in 60% of the primary GBM (Xu et al., 
2017), the mammalian Target of Rapamicine (mTOR) and the Vascular 
Epithelial Growth Factor (VEGF) (Mohtashami et al., 2020).  
Another important target is the Nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-κB), a transcription factor that regulates many 
mechanism like cell growth, invasion, radioresistance and survival 
(Srivastava et al., 2017; Duerinck et al., 2015). Inhibit NF-κB in GBM 
could be crucial also for its ability to mediate TMZ resistance through the 
MGMT regulation (Qian et al., 2015). 
2. Monoclonal antibodies (mAbs). In spite of significant results obtained 
in different cancers such as hematological, renal and breast (Lim et al., 
2018), trials using mAbs against GBM didn’t show the expected results 
(Mohtashami et al., 2020). The main target of this mAbs is EGFR since is 
overexpressed in GBM and is located on the cell membrane. 
Nevertheless, a mAbs against CD95 used in a phase II trial was able to 
extend the survival of recurrent GBM patients (Blaes et al., 2018), 
switching on again the research on immunetherapy against GBM. 
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3. Immune check point inhibitors. A particular class of mAbs targets the 
immune check point inhibitors such as Programmed cell Death 1 (PD-1) 
and its Ligand (PD-L1) and Cytotoxic T-Lymphocyte Antigen 4 
(CTLA-4). The inhibition of these molecules should reactivates the T-Cell 
enhancing the tumor cell immune response (Caccese et al., 2019). The 
efficacy of these mAbs  have been evaluated in different trials and 
different combination among them or other kinds of  treatment, 
suggesting that the use of these mAbs could represent an important step 
forwards in GBM treatment (Lowther, et al., 2016; Reardon et al., 2016; 
Reardon et al., 2017; Omuro et al., 2018).However, the inhibition of the 
check points in GBM didn’t demonstrate sufficient efficacy in clinical 
trials, failing to improve the survival of the patients (Brahm et al., 2020). 
A possible way to ameliorate the efficacy of these therapies could be the 
employment of multi-modal approach to activate local and systemic 
tumor-specific immune responses. 
4. Vaccines. Vaccination stimulates the body’s tumor-specific immune 
response by the injection of foreign antigens. Vaccines against GBM are 
primarily of two categories: peptide and cell-based vaccines. Peptide 
vaccines involve the injection of tumor specific antigens. The 
characterized targets for GBM peptide vaccines are EGFRvIII, Survivin 
and the Heat Shock Protein (HSP) (Mohtashami et al., 2020). However, 
despite good results of phase I/II clinical trials, no successful phase III 
clinical trials have been reported to date. Cell-based vaccines (dendritic 
and/or tumor cell vaccines) are based on the injections of ex vivo-
modified cells (Kong et al., 2017). 
5. Adoptive cell therapy and CAR T. Adoptive cell therapy aims at 
infusing immune cells with direct anti-tumor activity in order to 
reestablish the anti tumor activity of the immune systems (Wang et al., 
2020). The most promising approach of adoptive cell therapy is the use of 
genetically modified T cells with chimeric antigen receptors (CARs). To 
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generate CAR T cells, T lymphocytes are transduced with CAR 
constructs containing a Tumor-Associated Antigen (TAA) recognition 
domain linked to the constant regions of a signaling T cell receptor (Land 
et al., 2020). In GBM treatment, CAR T cells are still at the early phase of 
development. The more promising CAR T targets are Interleukin-13 
receptor alpha 2 (IL13Rα2), EGFRvIII and HER2. So far, clinical trials 
have demonstrated the safety of these approaches (Land et al., 2020), 
encouraging to keep on the research on CAR T lymphocyte. 
6. Oncolytic virotherapy. This therapeutic option is based on the ability of 
viruses to infect and selectively replicate in cancer cells. Their infection 
should lead to tumor cell death without harming healthy cells (Chen et al., 
2012). Oncolytic therapy has been applicator in different trials in GBM 
treatment and, in some cases, has shown amazing results, prolonging the 
OS of many months respect the conventional therapy (Mohtashami et al., 
2020). A particular aspect of oncolytic virus is the possibility to be 
engineered in order to express immunemodulatory   transgenes able to 
enhance the immune infiltration and response against GBM. Open studies 
are trying to determine the efficacy as immunomodulatory of cytokines 
(IL-4, IL-12 or IL-15), immune checkpoint inhibitors (Anti PD-1) or 
oncogenes (PTEN, p53) (Zhang et Liu, 2020) 
2.1 GBM challenges 
Despite ongoing research, the outlook on GBM remains quite disappointing. The fact that 
treatment and prognosis have remained unchanged for fifteen years leads to the realization 
that there are major challenges that we have not been able to overcome. Among all the 
difficulties on GBM management, there are three main challenges that lead to treatment 
failure:  
1. The presence of the Blood-Brain Barrier 
2. The tumor itself 
3. the toxicities of current treatments  
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2.1.1 The Blood Brain Barrier 
The CNS required a high controlled microenvironment to guarantee the normal functioning 
of the brain. CNS isolation from the rest of the body is protect by the presence of three 
biological barrier composed of different cell types and established at three pivotal 
interfaces: i) the Blood-Brain Barrier (BBB), created by the endothelial cells of the vessel 
to separate the brain from the blood component, ii) the Blood-Cerebrospinal Fluid Barrier 
(BCSFB), formed by the epithelial cells of the choroid plexus to separate the CSF from the 
brain, and iii) the arachnoid barrier, provided by the avascular arachnoid epithelium to 
enwrap the CNS under the dura madre (Abbott et al., 2013) (Fig. 5). 
 
Fig. 5: Biological barriers that protect the brain. The brain is protected by biological barrier at three different levels. 
a) Blood–brain barrier protect the brain from the blood component and regulate nutrients and molecules passage; b) 
blood–CSF barrier separate the brain from the cerebrospinal fluid; c) the arachnoid barrier. ISF Interstitial Fluid. Adapted 
from Kadry et al., 2020. 
Due to its peculiar structure, BBB is the main responsible for CNS protection and 
homeostasis maintenance. Brain microvascular endothelial cells have peculiar 
characteristics that make them different from the vessel located in other parts of the body. 
Among them, three are the most important (Kadry et al., 2020): 
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1. The presence of Tight Junctions (TJ) between the cells that prevents the 
passive passage of polar molecules between blood and brain 
2. The absence of fenestration between the cells 
3. The regulation of the passage of the essential molecule with specific 
transporters and the presence of the efflux mechanisms. 
Beyond the endothelial level, the BBB is organized with other cell types in a 
Neurovascular Unit (NVU). Indeed, the endothelial cells are cover by the pericytes with in 
turn are embedded by the basal lamina. Finally, the endfeet of the astrocytes enwrap the 
vessels establishing the NVU (Zlokovic, 2011) (Fig. 6). 
Fig. 6: Neurovascular unit structure. The blood vessels of the brain are organized with other cells in structure named 
neurovascular unit. The endothelial cells, strictly bind each other by the TJ, are surrounded by the pericytes and the basal 
lamina. Finally, the astrocytes covered the entire structure with their endfeet and ultimate the highly impermeable 
structure of the BBB. 
BBB free diffusion is possible only for lipophilic molecules smaller than 400 Da that can 
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and CO2 diffusion in the opposite direction is extremely rapid in order to maintain normal 
brain metabolism and regulate the pH in the Interstitial Fluid (ISF) and other cells (Kadry, 
2020). The involvement of a ligand specific transporter is needed to regulates the passage 
of nutrients, metabolites, energy molecules, such as glucose cholesterol, and other 
molecules from blood vessel into the brain parenchyma. In the same way, metabolic waste 
products are transported from brain parenchyma into the blood (Zhao et al., 2015).  
The main mechanism that regulates macromolecules crossing through the BBB is 
transcytosis that allow the transport of macromolecules from the apical to the basolateral 
plasma membranes of endothelial cells. 
There are two main categories of transcytosis in the CNS (Fig. 7) (Ayloo and Gu, 2019): 
1. Adsorptive transcytosis: charged 
molecules, like albumin, interact 
with the plasma membrane and this 
facilitate the transport across the 
endothelial cell; 
2. Receptor Mediated Transcytosis 
( R M T ) : l i g a n d s , i n c l u d i n g 
transferrin, and macromolecules like lipoproteins bind their receptors on cell 
membrane and this assure the BBB crossing. 
Fig. 7: Transcytosis in CNS endothelial cells. RMT and adsorptive transcytosis. In both mechanism, the molecules are 
internalized into an endosome and transported through the cell to the basolateral cell membrane. Adapted from Ayloo and 
Gu, 2019. 
An example of RMT is represented by lipoproteins and their receptors. Among them, 
Apolipoprotein E (ApoE), a multifunctional protein with central role in CNS lipid 
metabolism (Pirmoradi et al., 2019). By binding to the Low Density Lipoprotein Receptor 
(LDLR) expressed on the luminal membrane of the endothelial cells ApoE allows the 




























Once the molecules interact with the endothelial cell by both RMT or charge interaction, 
they are internalized by endocytosis. Cell membrane invagination and cargo internalization 
are regulated by different proteins and pathways: 
1. Clathrin-dependent endocytosis: clathrin-coated pits generates at the level of 
molecule/cell membrane interaction; the GTPase dynamine facilitates the 
invagination release from the membrane and the formation of clathrin-coated 
vesicle (Sweitzer and Hinshaw, 1998) 
2. Caveolae-dependent endocytosis: plasma membrane invaginations called 
caveolae are formed by caveolins binding to cytosolic cavins. This interaction 
leadsendosomal vesicle  formation (Hill et al., 2008). 
In the cytoplasm, endocytic vesicles are sent trough tubules pathways to the basolateral 
membrane (Villaseñoret al., 2017), where vesicle membrane fuses with cell membrane 
allowing the release of their cargo to conclude the transcytosis (Pulgar, 2019) (Fig. 8). 
 
Fig. 8: Receptor Mediated Transcytosis of mApoE-lipoprotein. Schematic representation of ApoE-lipoprotein 
transcytosis from blood vessel to brain parenchyma. Adapted from Pulgar 2019. 
The BBB protective nature acts also in the case of drugs. In addition, the effectiveness of 
CNS targeted drugs is further limited by the presence of the efflux transport system 





Solute Carrier (SLC) are the two main classes of drug transporter present on BBB. ABC 
biological function is the active transports against concentration gradients of hydrophobic 
compounds, and consequently hydrophobic drugs, by ATP hydrolysis with P-glycoprotein 
(P-gp) (Mahringer and Fricker, 2016), encoded by multi drug resistance gene 1 (MDR1). 
SLC instead actively transports energetic substrates, amino acids, neurotransmitters and 
organic ions (Nałęcz, 2016),  driving the resistance of small molecule and peptide 
(Sanchez-Covarrubias et al., 2014). 
Drug efflux mechanisms are at the basis of many drug delivery failure in GBM. Among 
them is Doxorubicin (DOXO), an anthracycline antibiotic with antineoplastic activity 
isolated from the bacterium Streptomyces peucetius. DOXO functions primarily 
intercalating between base pairs in the DNA helix interfering with its uncoiling. 
Additionally, DOXO inhibits topoisomerase II which results in an increased and stabilized 
cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents 
the ligation of the nucleotide strand after double-strand breakage. DOXO also generate 
oxygen free radicals that contribute to the toxicity of the anthracycline antibiotics, namely 
the cardiac and cutaneous vascular effects (PubChem [Internet]. Bethesda (MD): National 
Library of Medicine (US), National Center for Biotechnology Information; 2004-. 
PubChem Compound Summary for CID 31703, Doxorubicin; [cited 2021 Feb. 26]. 
Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Doxorubicin). DOXO is 
currently used in the treatment of many tumor like non-Hodgkin’s and Hodgkin’s 
lymphoma, multiple myeloma, as well as lung, ovarian, gastric, thyroid, breast, sarcoma, 
and pediatric cancers (Cortés-Funes and Coronado, 2007). Its effectiveness has been 
demonstrated also against GMB cells in vitro but has poor efficacy in vivo due to extrusion 
by multidrug resistance-related proteins present on BBB (ABCB1/MDR1, ABCG2/BCRP, 
ABBC1/MRP1, ABCC2/MRP2, ABCC3/MRP3 and ABCC6/MRP6) that reduce the 
amount of drug that can reach the GBM cells. Moreover, also GBM cells express 
multidrug resistance-related proteins (ABCB1/P-gp, ABCG2/BCRP, ABCC1/MRP1, 
ABCC4/MRP4, and ABCC5/MRP5) further reducing the active drug inside tumor cells 
(Gomez-Zepeda et al., 2019). 
2.1.2 GBM itself 
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Cellular hierarchies related to the developmental programs of tissue stem cell and their 
lineage differentiation play a central role in many cancers. In GBM different cell sub-
populations can be isolated within the same lesion. Results obtained with single cell RNA 
sequencing strongly suggest that GBM intra cellular heterogeneity is due to gene 
expression programs that are normally active during neurodevelopment and are differently 
active in GBM cells (Darmanis et al., 2017; Neftel et al., 2019; Patel et al., 2014; Wang et 
al., 2019; Bhaduri et al., 2020). In this cellular heterogeneity the GBM Stem Cells (GSCs), 
also known as tumor-initiating cells, play a pivotal role in tumor progression and outcome 
due to their intrinsic refractoriness to conventional therapy and ability to invade the 
surrounding healthy tissue. Their malignancy is enhanced by their self-renewal ability, 
pluripotency, multilineage differentiation, high rate of proliferation, angiogenetic and 
immune response modulation capacity (Lathia et al., 2015). GSC typically growth in 
specific tumor compartments named niches. Three main niches has been 
histopathologically recognized: the perivascular niche near the brain vessel or in proximity 
of neoformed vessel (1); the hypoxic niche in the inner part of the tumor mass, far from 
vessel and, consequently, oxygen (2); the invasive niche in the outer part of the tumor in 
close contact with the brain parenchyma (3) (Hambardzumyan and Bergers, 2015) (Fig. 9).  
Fig. 9: GSCs niches. GBM are extremely heterogeneous tumor, composed by different cell subpopulations. Among 
them, GSCs represents one of the most abundant subpopulation. GSCs usually growth in specific tumor compartments 
called niches. Three different niches can be identify: the perivascular niche near the blood vessels; the hypoxic niche in 
the inner part of GBM core characterized by low nutrients and oxygen amount; and the invasive niche, corresponding to 






GBM heterogeneity can be described with different molecular signature. Similarly, GSCs 
can be identify by unique molecular signature. In the last 10 years the gene expression of 
specific markers has been largely investigated, focusing the attention on PN and MES 
subtype (Bath et al., 2013; Halliday et al., 2014; Moreno et al., 2017; Rooj et al., 2017; 
Minata et al., 2019):  
1. Pro Neural (PN): GSCs sharing some characteristics of the fetal Neural 
Stem Cells (NSCs). Among PN markers the most characterized are 
CD133, SOX2, SOX9, OLIG2 and ADGRG1 
2. Mesenchymal (MES): GSCs sharing characteristics of adult NSCs. Some 
of the most characterized MES marker are CD44, CTGF, FN1, CHI3L1, 
ALDH1A3. 
These signature of the GSCs is not fixed and invariable but could evolve in time from PN 
to MES in the so called Proneural to Mesenchymal transition (PMT), a change in 
molecular characteristics allowed by a high permissive epigenetic status (Banerji et al., 
2013; MacArthur et al., 2013) that makes GSC a cell population constantly evolving in a 
continuous dynamic flux (Chang et al., 2008). Multitherapy used to treat GBM in patients 
forced the PMT transition enriching the GSCs in MES signature. MES GSCs have been 
demonstrated to be extremely radio and chemo resistance and are the main cause of the 
recurrence unresponsiveness to therapy (Segerman et al., 2016). PMT and the high GSCs 
variability within the tumor could be explain by the plethora of stimuli that these cells 
receive like alteration in the microenvironment, drug treatments and GSC interaction with 
other cells, both GBM cells and not (Pisco et al., 2013). 
In a recent model, Prager et al. described these stimuli as “attractors” able to generate local 
microenvironment different from that of the original tumor. The high stemness and entropy 
of GSCSs make these cells more prone to react and change in response to surrounding 
stimuli, generating new signature and sub-population. In this prospective, therapeutic 
treatments could not only select a GSCs resistant to treatment but they could also generate 





Fig. 10: Attractor state model. Multipotent GSCs have the highest level of entropy and ability to differenziate in 
response to different attractors (e.g. genetic mutation, therapeutic treatments, oxygen or nutrient level). Different attractor 
states induce the development of different population. Adapted from Prager et al., 2020 
GSCs are the subpopulation with key role in tumor growth and recurrence (Singh et al., 
2004; Bao et al., 2006; Chen et al., 2012) and their increased resistance to chemo- and 
radio-therapies (Bao et al., 2006; Chen et al., 2012; Cheng et al., 2011) is directly related to 
refractoriness to conventional therapy. Known mechanism subtending drug resistance in 
GSCs included: 
1. Drug efflux by ABC transporters express on GBM cells including ABCB1/P-
gp, ABCG2/BCRP, ABCC1/MRP1, ABCC3, ABCC4/MRP4, ABCC5/MRP5 
and ABCC6 (Gomez-Zepeda et al., 2019; Jeon et al., 2011); 
2. DNA repair mechanisms such as DNA mismatch repair (MMR), base excision 
repair (BER) or by the action of a demethylating enzyme such as MGMT (Lee, 
2016) or KDM5 (Banelli et al., 2015). The inhibition of MGMT through 
promoter methylation has been largely studied in the last years (Hegi. Et al., 
2005; Park et al., 2011; Binabaj et al., 2018) and is currently considered one of 
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3. Selection of chemo- and radio-resistance subpopulation by cotreatment of TMZ 
and RT (Bao et al., 2006; Chen et al., 2012). These resistant GSCs are the main 
cause of GBM recurrence 
2.1.3 Current treatment toxicities 
Since 2005 the Stupp protocol is stably used for GBM treatment (Stupp et al., 2005). This 
protocol is set on maximal surgical resection followed by RT (usually 60 Gy in 30 fractions 
of 2 Gy, Dhermain, 2014) and adjuvant chemotherapy with TMZ (Fig. 11). Tis protocol 
allow to extend the  median survival of the patient to 15 months. However, the prognosis 
remain unfaithful and since then no significant step forward have been done. 
Fig. 11: GBM treatment protocol. Schematic representation of GBM treatment. After diagnosis, patients undergo GBM 
maximal resection by surgery. Then, they are treated with radiotherapy plus TMZ as adjuvant. 
CNS is generally resistant to radiation but the high dosage used in GBM treatment can lead 
to brain damage both in the acute and long term phase (Dropcho, 1991). Radio-induced 
brain damage is related to the dose administered, the dose per fraction and the duration of 
the treatment, the volume of the GBM and is dependent to the interaction of the brain cells 
that composed the tumor microenvironment (Cuccurullo et al., 2019). Indeed, besides the 
fixation of the DNA double strand brakes that principally hit the tumor cells, other 
mechanisms of radio-toxicity damage the the brain tumor, such as oxidation of the lipid 
bilayer, microvascular permeability, rearrangement of the cell-cell junctional complexes 
and mitochondrial alteration (Cuccurullo et al., 2019). 
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Diagnosis Surgery Radiation TMZ
The neuro-inflammation induced by the RT is particularly critical for the brain cells. The 
H2O free radicals generated by RT induced the production of Tumor Necrosis Factor α 
(TNFα) and Interleukin 1β (IL-1β) by the glial cells (Kam and Banati 2013). The absence 
of endogenous anti oxidant and the high metabolism of the brain cells make this cells 
particularly sensible to the oxidative stress (Grunert et al., 2018) 
Another severe local tissue reaction to RT is the Radiation Necrosis (RN) that appears 3-12 
months after the treatments with a not well understood pathophysiology. RN is 
characterized by necrosis of blood vessel walls and the presence of adjacent perivascular 
parenchymal coagulative necrosis , while the change in the white matter observed are 
mainly focal and diffuse demyelination (Zikou et al., 2018). 
Along with RT, patients receive the administration of the chemotherapy agent TMZ. TMZ 
is an adjuvant drug TMZ and, as a chemotherapy agent, is obviously related to severe side 
effect. Patients receiving TMZ are at risk for hematologic toxicity and should be monitored 
with weekly complete blood counts (CBCs). At least 15% and up to 75% of the patients 
suffer of moderate to severe lymphopenia and neutropenia, showing an extremely low 
CD4+ T cell counts after six weeks of daily TMZ with concurrent radiotherapy (Grossman 
et al., 2011). A mild and self-limited aminotransferase elevations occur in up to 12% of 
patients 2-8 weeks after the start of the treatment but several patients had received multiple 
courses before the onset of liver injury. In addition, TMZ has been associated with several 
cases of reactivation of chronic hepatitis B in patients who were hepatitis B surface antigen 
(HBsAg) positive at the start of chemotherapy. (PubChem [Internet]. Bethesda (MD): 
National Library of Medicine (US), National Center for Biotechnology Information; 2004-. 
PubChem Compound Summary for CID 5394, Temozolomide; [cited 2021 June 25]. 
Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Temozolomide). 
Many other undesired reactions to TMZ may occur during assumption including: 
3. Bruising, bleeding gums or nose bleeds 




6. Feeling or being sick  
7. Tiredness 
8. Seizures (fits) 
9. Weakness on one side of the body 
10. Hair loss 
11. Skin rash  
Due to these side effects, the use and dosage of RT and TMZ must be limited to avoid 
excessive toxicity. Consequently, the efficacy of the Stupp protocol cannot be modify even 




In the last two decades, Nanomedicine shows great promise in the treatment of tumor. The 
delivery of drugs via nanoparticles helps to improve the performance of anti-cancer drugs 
in terms of bioavailability, safety and specificity. Taking advantage of molecular markers 
over-expressed on tumor tissues compared to normal cells, an “active” molecular marker 
targeted approach should increase drug concentration at the tumor site, improving efficacy, 
reducing chemo-resistance and off-target side effect. 
In GBM, the first and probably most complicated issue that nanomedicine have to face is 
the cross of the BBB, in particular in the peripheral region of the tumor. 
3.1 The Blood-Brain Tumor Barrier 
In the GBM context the BBB shows different states and BBB impairment is not uniform. 
The interface between BBB and the tumor is called Blood-Brain Tumor Barrier (BBTB) 
(Khan et al., 2021). At the level of the core tumor mass, BBB is heavily altered and its 
impermeability is impaired by the down regulation of claudin-1, a pivotal component of 
the TJ in endothelial cells (Khan et al., 2021). However, at the interface with the tumor 
edge, characterized by the presence of invasive GSCs, BBB maintains intact its structure 
and permeability (Costas D. Arvanitis et al., 2020, Jann N. Sarkaria et al., 2018) (Fig. 12): 
Fig. 12: heterogeneous disruption in GBM. Significant BBB breakdown seen in the bulk tumor region (left panel) 
allows drugs and cells extravasation. Regions with infiltrating GBM and GSC cells show less or no breakdown of the 
BBB (right) preventing therapeutics to reach these cells. 
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As complete tumor resection is impossible to achieve, reaching GBM cells remaining after 
surgery at the periphery of the tumor where an intact and still impermeable BBB represents 
the main obstacle to GBM treatment (Costas D. Arvanitis et al., 2020). 
Several efforts are currently under study to bypass this problem. One of the most 
promising is the specific targeting of GBM cells with drug loaded nanoparticles. 
3.2 Nanoparticles 
Nanoparticle (NP) is defined as a particle of matter that is between 1 and 100 nanometres 
(nm) in size. NPs can be divided into three main groups: organic (lipids, proteins or 
polymers); carbon-based; and inorganic (metals or salts) (Buzea et al., 2007). The multi-
faceted physiochemical properties of these materials allow NPs to be suitable for the most 
diverse applications at the molecular level. Because of their characteristic ultra-small 
dimensions, their ratio surface-area to volume is rather high, giving the possibility of 
ultimately refining the size, shape, chemical properties, surface functionalization and 
biologic capacities based on the specific application (Fig. 13) such as diagnosis, gene and 
drug delivery, vaccines and tissue engineering (Soares et al., 2018). 
Fig. 13:  Designing nanoparticles for intracellular applications. NPs can be synthesized varying their composition 
(organic, carbon based or inorganic core), physical properties (shape, size, porosity,…), targeting ligand and surface 
chemistry in order to obtain the best drug delivery system for each specific necessity. Adapted from Adikhari et al., 2019 
One of the most promising field of nanomedicine is the treatment of cancer. Indeed, the 
delivery of drugs via NPs helps to improve the performance of anti-cancer drugs in terms 
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of bioavailability, safety and specificity. Accordingly, NPs can improve drug's therapeutic 
effectiveness while reducing adverse side effects associated with high dosage. 
3.3 Drug-loaded nanocarriers 
A nanocarrier is a NP used as a transport module for another substance including 
chemotherapeutics, nucleic acid and other active molecule. Among the most commonly 
used nanocarriers are lipid bilayer vesicle (liposome), and polymeric web composed of 
repeated self-assembling polymer chain (Jain and Thareja 2019). 
The first FDA approved nanovector for drug-delivery was Doxil®, a liposomal form of 
DOXO for the treatment of ovarian and breast cancer (Song et al., 2012; Schwendener 
2007; Torchilin 2005; Maurer et al., 2001). DOXO is one of the most commonly used 
chemotherapeutic agent for the treatment of a broad range of cancers but cardiotoxicity and 
myelosuppression limit its use. Liposome encapsulation constrains DOXO severe adverse 
effects (Rafiyath et al., 2012). However, liposomal DOXO has been shown to be inefficient 
against GBM in patients (Ananda et al., 2011). The poor clinical outcomes were 
presumably the result of the limited BBB crossing and other challenges inherent in tumor 
drug delivery (Lockman et al., 2010) .  
The main strategies used in tumors targeting by nanocarriers are: 
1. Passive targeting based on the Enhanced Permeability and Retention effect 
(EPR), firstly described by Matsumura end Maeda in 1986 (Matsumura end 
Maeda, 1986). NPs accumulate in tumor tissue thanks to the presence of 
fenestrated blood vessels and an inadequate lymphatic drainage (Moghimi et 
al., 2001; Fang et al., 2011). Passive targeting works at the level of GBM core, 
where the BBB structure is highly compromised and fenestrated but it is not 
efficient to reach peripheral tumor cells that invade the healthy parenchyma 
where the BBB structure is preserved. Here, the EPR effect is insufficient to 
allow nanocarriers targeting of GSCs responsible for cancer recurrence (Lemée 
et al., 2015). 
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2. Active targeting is achieved through the decoration of the nanocarrier surfaces 
with ligands binding to receptors over-expressed on the tumor cells and their 
microenvironment. This strategy will improve the affinities of the nanocarriers 
for the surface of cancer cell and thus enhance the drug penetration. Moreover, 
in the case of GSC invading cells, active targeting can help nanocarriers to 
cross the BBB and GBM cells targeting.  
The major challenge of a nanocarrier-based therapy for GBM is the finding of the best 
targeting strategy for BBB crossing and drug delivery at the specific site. 
3.4 Active targeting strategies 
It is well recognized that active targeting is essential for the efficient delivery of drugs, 
genes and theranostics to the location of interest avoiding normal tissues and thereby 
enhancing therapeutic efficiency and limiting side effects. Active targeting is able to 
significantly increase the quantity of drug delivered to the target cells compared to free 
drug or passively targeted nanosystems.  
3.4.1 Ligand-modified nanocarriers  
Coating specific targeting ligand(s) on the surface of nanoparticles is the most common 
strategy of active targeting. These targeting ligands could be in the form of small 
molecules, peptides, antibodies, designed proteins, and nucleic acid aptamers (Liu et al., 
2009; Friedman et al., 2013). The main goals of active strategy in GBM are (I) BBB 
targeting and crossing, in order to accumulate a higher drugs amount at tumor site respect 
passive targeting, and (II) specific tumor targeting, in order to reduce drug delivery to non-
cancer, healthy cells. 
BBB crossing by active targeted nanocarrier can be achieved by Receptor Mediated 
Transcytosis (RMT) (Jones and Shusta, 2007). After ligand/receptor binding, nanocarriers 
are internalized into endothelial cells by endocytosis. 
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One of the most studied ligands used to take advantage of RMT in nanocarriers delivery to 
the brain is Transferrin (Tf). For example, the presence of Tf receptor at the BBB allows 
Tf-liposome to accumulate 13 times more in the brain respect to unconjugated liposome 
(Soni et al., 2005). Similarly, cyclic Arg-Gly-Asp (cRGD) enhanced tumor uptake of 
micelles loaded with oxaliplatin in a orthotopic mouse GBM model,  reducing tumor 
growth, thanks to cRGD binding of αvβ3 and αvβ5 integrins overexpressed on tumor 
vasculature and tumor cells (Miura et al., 2013). 
Due to its capability to interact with the lipoprotein receptor-related protein (LRP), which 
is highly expressed on the BBB, it has been already reported that the use of Angiopep-2 
enhances the delivery of genes into the brain through the BBB (Ke et al., 2009). Since LRP 
is also overexpressed in human GBM cells, Angiopep-2 can be used as a dual targeting 
agent, enhancing both endocytosis across the BBB and a successful targeting of GBM cells 
(Xin et al., 2011). 
Thanks to an extensively reprogrammed cellular metabolism, tumor cells survive and 
proliferate under nutrient and oxygen deprivation. In this context, GBM cells are highly 
dependent on cholesterol supply for survival (Geng et al., 2016) and rely on exogenous 
cholesterol uptake, mediated by the Low-Density Lipoprotein Receptor (LDLR) (Villa et 
al., 2016). Indeed, LDLR is expressed in GBM and its upregulation correlates with tumor 
progression and drug resistance (Geng et al., 2016; Guo et al., 2011; Maletinska et al., 
2000). LDLR expressed at the BBB (Wagner et al., 2012) is crucially involved in the 
transport of macromolecules from the blood stream to the brain by RMT (Fung et al., 
2018; Pulgar 2018). LDLR binds and internalizes Apolipoprotein E (ApoE)-containing 
lipoproteins which mediate the brain metabolism of cholesterol (Pirmoradi et al., 2019). 
Several nanoscale drug delivery systems involving ApoE-conjugated nanoparticles are 
currently under investigation as potential vectors to deliver pharmacological agents across 
the BBB for the treatment of central nervous system disorders (Dal Magro et al., 2017).  
3.4.2 Activatable nanocarriers 
One of the most recent and promising targeting strategies aims to create nanovector that 
maintain the stealth property during circulation and then transform to a more cell-
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interactive form (active targeting) upon arrival at the target tumor sites (Gullotti and Yeo, 
2009). This strategy aims to mitigate the side effect of the treatments by localizing the drug 
release. Moreover, this localized release could increase the drug concentration at the tumor 
site, enhancing the drug effective dose. 
Nanocarrier activation could be achieved by two main mechanisms (White et al., 2019): 
1. Extrinsic activation: takes advantage of external physical stimuli including 
ultrasound, magnetic field, light and X-ray to active the nanocarriers 
2. Activation by altered cancer cell metabolism: it takes advantage of the 
unique characteristics of tumor microenvironment. 
In the last years ultrasounds have been largely studied as extrinsic nanovectors activation. 
Circulating microbubbles  hit by Focus Ultrasound (FUS) can effectively increase the 
permeability of BBB by stretching the blood vessel and creating transient opening of the of 
the tight junction (Deng et al., 2019). Dual administration of microbubbles and nanocarrier 
could effectively increase the accumulation of drugs at tumor site (Fisher and Price, 2019). 
However, despite the promising results, more detailed studies are required to prove the 
efficacy of this mechanism. 
Tumors develop unique microenvironments such as slightly acidic pH (Gerweck and 
Seetharman, 1996) and an a high level of proteinases (Egeblad and Werb, 2002). The 
tumor extracellular pH is generally more acidic (pH 6.5 to 7.2), due to the increased 
glycolysis and plasma membrane proton-pump activity of tumor cells, which make them 
produce more lactic acid than normal cells and leach out the acid to the extracellular milieu 
(Swallow et al., 1990; Montcourrier et al., 1997). Normal tissue has a pH of around 7.4 
(Qian et al., 2012). Certain nanocarriers will only release the drugs they contain in 
specific pH ranges. pH-responsive micelle conjugated with a novel moiety against 
overexpressed cell surface platelet derived growth factor receptor (PDGFR), loaded with 
TMZ, are able to target PDGFR on GBM cells. This results in pH-dependent release of 
TMZ preferably in tumor tissue, thereby reducing systemic toxicity. pH sensitive micelles 
exhibit specific uptake and increased cell killing in GBM cells and accumulated in brain 
tumor tissues (Miller at al., 2016).  
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The overproduction of enzymes such as the matrix metalloproteinases (MMPs) is also 
common in most tumors, because MMPs are important for angiogenesis, metastasis, and 
other extracellular signaling events involved in tumor propagation (Egeblad and Werb, 
2002). Early expression of MMPs, either by the tumor cells themselves or by surrounding 
stromal cells, helps to remodel the  Extra Cellular Matrix (ECM) and release ECM and/or 
membrane-bound growth factors, which provides a favorable microenvironment for the 
establishment of the primary tumor. As the tumor grows, an angiogenic switch occurs 
(possibly in part because of hypoxia) in which the balance of proangiogenic factors (e.g., 
bFGF and VEGF) overcomes the expression of angiogenic inhibitors (e.g., 
thrombospondins, angiostatin, and IFNs) (Hanahan and Folkman, 1996). Both MMP-2 and 
MMP-9 have been implicated in the induction of the angiogenic switch in different model 
systems (Egeblad and Werb, 2002).  Further up-regulation of MMP expression, in 
particular the gelatinases, which can degrade basement membrane components, allows the 
tumor cells to invade into the adjacent stroma and to break down the basement membranes 
associated with capillaries and lymphatic vessels allowing tumor cells to enter the 
circulation (intravasation) (Chambers and Matrisian, 1997). MMPs are also involved in 
cell migration by removing sites of adhesion, exposing new binding sites, cleaving cell-cell 
or cell-matrix receptors, and releasing chemo-attractants from the ECM (McCawley and 
Matrisian, 2011). Similar to intravasation, MMPs are necessary for the circulating tumor 
cells to be able to exit the blood vessels (extravasation), although this step does not appear 
to be rate limiting for the establishment of metastases (Chambers and Matrisian, 1997). 
MMP overexpression has been explored as a way of “turning on” imaging agents and 
locating tumors or other lesions (Mok et a., 2009; Lee et al., 2008; Scherer et al., 2008; 
Wunder et al., 2004; Weissleder et al., 1999) 
In GBM MMP2 expression correlates in GBM with high malignancy and poor prognosis 
(Ramachandran et al., 2017). MMP2 activatable nanocarriers have shown promising 
results in vitro and in vivo rat model of GBM (Gu et al., 2013). However, more detailed 
experiments and more precise in vivo model, such as Patient Derived Xenograft (PDX), are 
required to better understand the suitability of this system as drug delivery. 
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3.5 Nano-therapies for GBM treatment 
In the last years many attempts have been done to develop NPs suitable for GBM, from 
drug delivery to diagnostic and imaging (Wiwatchaitawee et al., 2021). Nanodrugs 
investigated in GBM are platforms with different backbones, such as vesicles (liposome, 
micelles), linear polymers, metals (Au, Gd,), carbon dots, dendrimers (Prasad et al., 2018), 
and increasing complexity of functionalizations. Agents active against GBM such as 
immune entity, chemotherapeutic/anti-angiogenic drugs or sensitizers could be load inside 
the NV core while specific moieties able to target GBM cellular receptors/angiogenic 
blood vessels or to open the BBB are bind at its surface (Wadajkar et al., 2017). Two 
higher levels of complexity are i) the possibility to associate fluorescent/radioactive 
compounds to enable NVs localization in the organism (Gonawala and Ali, 2017) and  ii) 
the possibility to activate NP on demand by an external source of energy such as X-rays, 
ultrasounds, or alternating magnetic field (Sneider et al., 2017) (Fig 14). 
  
Fig. 14:  Increasing complexity of NPs for GBM treatment. NPs development required extremely precise engineering 
starting from the material of the backbone (or core) of the NP. The complexity of the NPs can be increased by different 
functionalization  such as the active principle we choose to give efficacy to the treatment and the targeting entity to give 
specificity to GBM cells. The system can be further complicated by the adding of compound useful for imaging or 
detection such as fluorescent molecules or contrast agent. The highest level of complexity for a NPs is the possibility to 
be activated on demand by external physical sources like radiation, ultrasound or magnetic field. Adapted from 
Alphandéry, 2020 
In the last years many attempts have been done to combined NVs standard treatments, for 
example RT, in GBM treatment. It has been demonstrated that fractionated dose of 2Gy (to 
a maximum dose of 20-30 Gy) increases the BBB permeability (van Vulpen et al., 2002) 
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dose radiation is sufficient to improve the BBB crossing of nanoparticles in in vivo 
experiments (Tamborini et al., 2016). 
Fig. 15: BBB breakdown after irradiation. Sublethal dose radiation induce transient BBB breakdown and consequent 
enhance permeability. This represents a useful therapeutic mechanism to reach the single GBM cells disperse into the 
healthy parenchima., for example with nanoparticles as demonstrated by Tamborini et al., 2016. 
Only a small number of all the NVs under investigation were studied in clinical trial. 
Indeed, only 6 NP based drugs have reached phase I or II clinical trials (Fig. 16). Despite 
NPs are well tolerated and did not exert severe side effects, non of these regimens do 
significantly improve patients’ outcome in terms of progression free survival and overall 
survival (Hsu et al., 2021) 
Fig. 16: Clinical trials using nanotechnology and nano carrier based delivery system for treating GBM. Adapted 
from Hsu et al., 2021. 
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Tabella 1
Name Case number/patients Formulation/composition Main results
Nanothermotherapy 
Phase II 59 patients with recurrent GBM
Thermotherapy and Magnetic 
iron-oxide nanoparticles + reduced 
dose radiotherapy
This combination is safe and effective, 
leading to longer overall survival.
EDV-doxorubicin 
Phase I
14 patients with recurrent GBM 
expressing EGFR
EnGenelC delivery vehicle 
(EDV)-doxorubicin + radiation 
and oral TMZ
EDVDox was well tolerated, with no dose 
limiting toxicity and no withdrawals 
from the study due to adverse events.
Interleukin-12 
Phase I, II
Adult patients with recurrent 
GBM
Semliki Forest virus vector 
carrying IL-12 gene encapsulated 
in cationic liposomes
Liposomally encapsulated virus can be 




95 GBM patients were randomized 
after surgery
5-fluorouracil-releasing 
microspheres followed by early 
radiotherapy
Only slightly increased overall survival in the 
study group when compared with 
those received radiotherapy alone.
Caelyx, PEG-Dox 
Phase I, II
63 patients with newly diagnosed 
GBM
Pegylated liposomal doxorubicin + 
prolonged TMZ and radiotherapy
The progression free survival after 12 months 
was 30.2%, and the median overall 
survival was 17.6 months. Neither the 
addition of PEG-Dox nor prolonged 




40 patients with newly diagnosed 
GBM after surgery
TMZ and Pegylated liposomal 
doxorubicin after radiotherapy and 
surgery
The progression free survival after 6 months 
was 58%, and the median overall 
survival was 13.6 months. Combination of 
temozolomide and PEG-Dox does not 
add clinical benefit.
The limited number of patients included in the trials and the lack of a specific targeting 
system that confer BBB crossing and GBM specificity could be the main reasons for the 
lack of significance.  
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Rationale of the study 
The ultimate goal of the project is the synthesis of multi-task targeted, drug-loaded 
nanovectors able to penetrate GBM tumors and release chemotherapeutics for GBM 
treatment. To this end the research activity focused on three essential requisites to assure 
therapeutic efficacy to the drug delivery nanovectors:  
1. BBB crossing aptitude 
2. selectivity to GBM that includes GSCs and surrounding microenvironment 
3. Reduced drug toxicity 
Considering the crucial involvement of the LDL-receptor in the transport of 
macromolecules from the blood stream to the brain, the mApoE peptide known to confer 
BBB crossing capacity to nanovectors in the context of neurodegenerative diseases 
(Dehouck et al., 1997; F, Re et al., 2011; C. Balducci et al., 2014) was selected as BBB 
targeting moiety. 
Two strategies were investigated to achieve specific GSCs targeting and commitment to 
cell death: 
1. The mApoE peptide - Thanks to an extensively reprogrammed cellular 
metabolism, tumor cells survive and proliferate under nutrient and oxygen 
deprivation. In this context, GBM cells are highly dependent on cholesterol supply 
for survival and rely on exogenous cholesterol uptake, mediated by LDLR (Villa 
et al., 2016). Indeed, LDLR is expressed in GBM and its upregulation correlates 
with tumor progression and drug resistance (Geng et al., 2016; Guo et al., 2011; 
Maletinska et al., 2000). Moreover, LDLR is highly expressed at the BBB 
(Wagner et al., 2012) and is crucially involved in the transport of macromolecules 
from the blood stream to the brain, by RMT (Fung et al., 2018; Pulgar et al., 
2018). LDLR binds and internalizes Apolipoprotein E (ApoE)-containing 
lipoproteins which mediate the brain metabolism of cholesterol (Pirmoradi et al., 
2019). Therefore, a peptide derived from ApoE (mApoE) should assure to a 
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nanovector the two main issues of glioblastoma treatment: the BBB transcytosis 
and cancer cell specific targeting (Fig. 8). 
 
Fig 8: mApoE dual-targeting strategy simultaneously targeting BBB and GSCs. A) Schematic representation of 
mApoE-NV BBB crossing by RMT. Upon mApoE-LDLR interaction on the apical membrane of endothelial cells, 
mApoE-NVs are internalized (1). The endosome transports the complex to the basolateral membrane (2) where the 
mApoE-NVs are released into brain parenchyma. B) Schematic representation of mApoE-NV internalization into GSCs. 
After mApoE-LDLR mediated cell uptake and internalization (1), NVs inside endosome are degraded (2) and the DOXO 
released in the cytoplasm and penetrates into the nucleus. 
2. MMP-Activable Low Molecular Weight Protamines (LMWPs) - Taking 
advantage of the remarkable upregulated expression of MMP-2 and -9 in the GBM 
tumors (Ramachandran et al., 2017),  and in order to increase nanovector cellular 
uptake and GBM tumor specificity, a strategy based on the use of Cell Penetrating 
Peptides (CPP) coupled to an MMP2/9 activatable peptide sequence was 
investigated. Protamines are short peptides enriched in arginine that confers them 
high cell penetrating ability. As the non-selective mechanisms of cellular entrance, 
LMWPs generate important side effects when utilize to deliver drug-loaded NVs. 
The link of LMWP to a MMPs-sensitive sequence makes LMWP-NVs activable 
(ALMWP-NVs) in MMPs rich environments like the tumor microenvironment. 
When MMP2 cleave the cleavable PLGLAG sequence, polyanionic domain is 
separated by polycationic one, allowing LMWP-cell membrane interaction and 
LMWP uptake (Fig. 9). This would assure reduced unspecific interaction in tissue 
where MMPs are low or absent like brain healthy parenchyma and blood. 
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Fig 9: ALMWP assembly and mechanism of action. A) CPP sequence (Low Molecular Weight Protamine, LMWP) is 
linked to the E10 polyanionic sequence by a MMP2 cleavable sequence (PLGLAG). Negative charges on the E10 
polianionic sequence counterbalance the positives on CPP inhibiting its interaction with the cell membrane. B) Schematic 
representation of mechanism of action of ALMWP functionalized NVs. When the ALMWP-NVs is in the MMP2 
enriched tumor microenvironment, PLGLAG is cleaved by MMP2 enzymatic activity, CPP-NVs are separated from the 
E10 sequence and, consequently, LMWP positive charges can freely  interact with the cell membrane, negatively charged 
(1), allowing  NVs internalization in endosome (2). The NVs are subsequently degraded and the DOXO released in the 
cytoplasm where it penetrates into the nucleus and can intercalates the DNA (3).  
The different types of targeted nanovectors were chosen to deliver the chemotherapeutic 
agent DOXO. It was chosen as incapsulated drugs as paradigm of anticancer drug effective 
against GMB cells in vitro but with poor efficacy in vivo due to extrusion by multidrug 
resistance-related proteins present both on BBB and GBM cells (Gomez-Zepeda et al., 
2019). Furthermore, cancer cells exposed to DOXO elicit antitumor immunity by 
immunogenic cell death (ICD), a functionally unique form of cell death that occurs when 
apoptotic cells secrete distress signals called damage-associated molecular patterns 
(DAMPs) to trigger an antigen-specific immunity (Kroemer et al., 2013, Kawano et al., 
2016). A critical step for ICD is the engulfment of dying cells by professional macrophages 
and the activation of a variety of cells of the innate immunity, essential for the priming of 
the adaptive immune response (Galluzzi et al., 2017; Rapoport et al., 2019). Finally, 
DOXO exhibit severe side effects when administered as free drug (Zhao and Zhang 2017): 
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1. Nanovector BBB crossing and GBM therapeutic 
opportunities 
Different NPs based formulation have been tested for cancer treatment(Hsu et al., 2021). 
Among them DOXO-loaded liposomes (DOXO-LIPs), up to date, the only nanomedicines 
approved for solid tumor (Marchal et al., 2015; Wicki et al., 2015). Due to a significantly 
lower systemic toxicity, liposomal DOXO was the first FDA-approved nano-drug in 1995. 
In particular, liposomal-DOXO showed promising results as adjuvant agent in some solid 
tumor in particular breast cancer (Zhao et al., 2017; Li et al., 2019). Unfortunately, two 
different clinical studies conducted to assess the eligibility of liposomal-DOXO as GBM 
treatment did not reach significant prognosis and overall survival results,  actually 
unaltered  compared to standard protocol (Menei et al., 2005; Beier et al., 2009). The main 
cause of these failures was the inability of liposomal DOXO to cross BBB and, therefore, 
reach brain parenchyma and GBM (Ananda et al., 2011). 
It appears clear that NPs would not be effective on GBM without a system able to 
specifically target the BBB triggering NPs translocation into the brain. Among the possible 
mechanisms that could lead to BBB crossing, RMT is one of particular interest because it 
takes advantage of receptors expressed on the membrane of the endothelial cells that 
composed brain capillaries. 
In this prospective, the laboratory of the Nanomedicine Center (NANOMIB) of the 
University of Milano-Bicocca has developed a LIPs conjugated with a modify peptide 
derived from the protein component of the ApoE lipoprotein named  mApoE-LIPs. In two 
different studies they demonstrated their ability to cross the BBB and be effective to 
remove β-amiloid (Aβ) plaques in Alzheimer Disease models (Re et al., 2011; Balducci et 
al., 2014). Taking advantage from their long and outstanding expertise on the use of 
mApoE-LIPs, we collaborated with them to translate the LIPs to GBM treatment. To this 
end, mApoE-LIPs were loaded with DOXO (mApoE-DOXO-LIPs) in order to have system 
able to both cross the BBB by RMT through the mApoE/LDLR interaction (Wagner et al., 
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2012) and, moreover, possibly target GSCs in the brain parenchyma (Geng et al., 2016; 
Guo et al., 2011; Maletinska et al., 2000). 
1.1 mApoE-LIPs and in vitro BBB crossing 
LIPs were synthesized by extrusion procedure mixing Sphingomyelin (Sm), Cholesterol 
(Chol) and PE-PEG-mal (48.75:48.75:2.5 molar ratio). Successively, LIPs were incubated 
with DOXO to obtain DOXO-LIPs and, finally, they were functionalized to obtain 
mApoE-DOXO-LIPs (Fig. 10 A). The final preparations were formed by mono dispersed 
LIPs of a diameter ranging from 102 to 128 nm and negatively charged (Fig. 10 B). Drug 
release kinetic from mApoE-DOXO-LIP demonstrate that LIPs are extremely stable 
nanovectors, having a DOXO release rate of just 0.11%/hr at pH 5 and 0.05%/hr at pH 6.5 
and 7.4 (Fig. 10 C). 
Fig. 10: characterization of mApoE-DOXO-LIPs. A) Schematic representation of Sphingomyelin (Sm)/Cholesterol 
(Chol) LIPs functionalized with mApoE peptide and embedding DOXO. B) cumulative DOXO release (%) over time 
from mApoE-DOXO-LIPs at pH 5.0, 6.5 of 7.4 at 37°C. The reported data are the mean of at least five different 
measurement ± SD. C) Physiochemical parameters of synthesized LIPs: mean diameter (size); polydispersion index 
(PDI) by dynamic light scattering (DLS); Zeta-poyrnyial (ζ-pot) by Zeta potential analyzer. All liposome preparations 
maintained a constant size and ζ-potential for up to 10 days within the experimental error (<2.6% of variation). The yield 
of DOXO encapsulation into LIP was 95±3% and the final preparation contained 220±12 µg of DOXO/µmol of lipids. 
The yield of LIP surface functionalization with mApoE peptide ranged between 55% and65% corresponding to 1.25% of 
total lipids. These data were kindly provided by Francesca Re (PhD) laboratory.
mApoE-DOXO-LIP ability to cross the BBB and target GBM cells was investigated in 
vitro using a transwell system integrated with a human brain capillary endothelial cell 
monolayer (hCMEC/D3), as a model of BBB (Fig. 11 A). A significant enhancement 
(approximately 5-fold) in DOXO permeation through the BBB was observed for mApoE-
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NV formulation Size ± SD (nm) Z-Potential ± SD (mV)
Polydispersion 
Index
LIP 102 ± 5 -25.51 ± 0,82 0,077
DOXO-LIP 117 ± 12 -18.74 ± 1.25 0,106
mApoE-DOXO-LIP 128 ± 15 -12.48 ± 2.02 0,081
A B
C
DOXO-LIPs compared to DOXO-LIPs without affecting LIPs integrity (Fig. 11 B, C). 
Moreover, mApoE-DOXO-LIPs didn’t alter BBB model transepithelial electrical 
resistance (TEER) and permeability compared to free DOXO,  indicating that the drug 
incorporation into LIPs reduces its cytotoxicity on non-target cells (Fig 11 D).  
In order to assess mApoE-DOXO-LIPs anti-tumor ability after BBB crossing, BBB model 
was integrated with GBM cells (U87MG and A172) in the lower chamber of the transwell 
(Fig. 11 E). Results in Fig. 11 F showed that the addiction in the upper chamber of 
mApoE-DOXO-LIPs, but not DOXO-lip, significantly reduced the viability of both 
U87MG and A172 cells by approximately 53% and 60% respectively after BBB crossing. 
Fig. 11: In vitro BBB crossing and GBM cell viability. A) Schematic representation of the in vitro BBB model prepared 
using hCMEC/D3 cells seeded on the transwell filter. B) EP to embedded DOXO determined by adding samples in the 
apical compartment and monitoring DOXO fluorescence in the basolateral one after 3h incubation. C) mApoE-DOXO-
LIP size after BBB crossing determined by nanoparticle tracking analysis of LIPs present in the basolateral compartment. 
D) TEER and EP to LY of endothelial monolayers after 3h incubation with DOXO (25µg/ml), free or embedded into 
LIPs. E) Schematic representation of the integrated transwell system prepared seeding adherent GBM cells in the 
basolateral compartment. F) hCMEC/D3 cells, in co-culture with U87MG or A172, were incubated with DOXO-LIPs or 
mApoE-DOXO-LIPs added in the apical compartment (DOXO 25 µg/ml). After 3h incubation, the transwell insert was 
removed and GBM cells viability was determined by MTT assay after additional 72h of culture. Pairwise comparison was 




NV formulation TEER (Ω cm2) EP of Lucifer yellow (cm/min)
CTR 41.12 ± 7 1.87 ± 0.6*10-3
DOXO-LIP 30.58 ± 9 1.48 ± 0.05*10-3
mApoE-DOXO-LIP 33.30 ± 11 1.53 ± 0.08*10-3




To verify that LIPs needed an active mechanism of internalization, GBM cells were treated 
with mApoE-DOXO-LIPs and DOXO-LIPs and analyzed by confocal microscopy. Results 
indicated a 3- to 6-fold increase of nuclear DOXO triggered by mApoE surface LIP 
functionalization (Fig. 12 A, B), suggesting the inability of LIPs to be internalized without 
a functionalization. Moreover, to confirm the receptor mediated and not unspecific 
internalization, cells were treated with the clathrin-mediated endocytosis inhibitor 
chlorpromazine (CPZ) and with the endocytosis inhibitor dynasore (DYN). mApoE-
DOXO-LIPs internalization was significantly inhibited in the presence of both the 
inhibitor, confirming that mApoE-DOXO-LIPs needed a receptor to be internalized by 
transcytosis (Fig. 12 C, D). 
Fig. 12: LIP internalization in GBM cells. A) Maximum projections of DOXO and Syto/DAPI merged signals acquired 
by means of confocal microscopy in U87MG cells incubated with liposomes (DOXO-LIP or mApoE-DOXO-LIP) or 
free-DOXO. B) Nuclear DOXO quantification in U87MG cells incubated with the indicated LIPs. C) Maximum 
projections of DOXO signals in U87MG cells incubated with mApoE-DOXO-LIP alone (CTRL) or in the presence of the 
endocytosis inhibitors chlorpromazine (CPZ) and dynasore (DYN). D) with mApoE-DOXO-LIPs alone (CTRL) or in the 
presence of CPZ and DYN. All data are reported as the mean of at least three independent experiments ± SD.Pairwise 
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1.2 LIPs cellular uptake and cytotoxicity in patient-derived GSCs  
One of the main causes of GBM recurrence is the presence of the GSCs able to invade 
brain parenchyma and resist to standard treatment (Singh et al., 2004; Bao et al., 2006; 
Chen et al., 2012; Bao et al., 2006; Chen et al., 2012; Cheng et al., 2011). Therefore, to 
investigate whether mApoE-LIPs could be exploited to target the tumor stem cell 
subpopulation, three GSC lines established from patient surgical samples named BG003, 
BG005 and GBM3 were treated with DOXO-LIPs and mApoE-DOXO-LIPs. 
GSCs were first tested in vitro for their ability to internalize functionalized LIPs. mApoE-
DOXO-LIP intracellular uptake was evaluated through nuclear DOXO fluorescence 
quantification. DOXO-LIP conjugation with mApoE significantly favored nuclear DOXO 
accumulation in all three GSC cultures (Fig. 13 A, B). Dose-dependent inhibition of cell 
viability was observed when GSCs were exposed to mApoE-targeted LIPs indicating that 
embedded DOXO was functional and effective. Conversely, non-targeted DOXO-LIPs did 
not affect GSC viability, even at the highest DOXO dosage, thus excluding cellular adverse 
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Fig. 13: LIP internalization and cytotoxicity in patient-derived GSC lines. A) Representative images of DOXO, 
DAPI and bright-field differential interference contrast merged signals in GCS3 cells incubated with mApoE-DOXO-LIP 
or DOXO-LIP. B) Nuclear DOXO quantification expressed as mean fluorescence intensity (MFI) ± SE normalized to 16 
MFI detected in cells incubated with DOXO-LIPs (4h, DOXO 4mg/ml). C) Cell viability after 48h incubation with LIPs 
at the indicated increasing DOXO concentrations. Values are expressed as mean percentage survival (six replicates ± SE) 
normalized to corresponding untreated. Pairwise comparison was performed by Student’s t-test.*P<0.05, ****P<0.0001.  
Considering that GBM standard treatment involve radiotherapy (RT) and that RT could 
alter protein expression (Wahaba et al., 2017), LDLR expression was measured in GSCs 
before and after a sub-lethal dose radiation of 2Gy, corresponding to the daily dose 
administered to the patients in a fractionated radiation protocol. BG003 and BG005 cells 
exhibited an approximate 2-fold and 4-fold increase of LDLR expression respectively 
while no LDLR modulation was observed in GBM3 cell cultures (Fig. 14 B). As a 
consequence, the radiation-induced LDLR expression was paralleled by higher levels of 
mApoE-DOXO-LIP uptake by BG003 and BG005 cells. Consistently with lack of LDLR 
induction, no difference in mApoE-DOXO-LIP uptake was observed in irradiated GBM3 
cells (Fig. 14 C). 
Fig. 14: effect of radiations on LDL-R expression and BBB permeability. A) Representative confocal images of 
irradiated (2Gy) and non-irradiated (0Gy) BG005 cells immunostained for human LDLR (red). In blue is the nuclear 
staining (DAPI). The cell bodies were defined by Phalloidin staining (green). B) LDLR level of expression in non-
irradiated (0Gy) and irradiated (2Gy) GSCs. The results are expressed as mean LDLR fluorescent area respect to non-
irradiated samples ± SE. C) Intracellular DOXO quantification in non-irradiated and irradiated GSCs incubated with 
mApoE-DOXO-LIPs. Results are expressed as MFI normalized to MFI of non-irradiated cells ± SE. Pairwise comparison 
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Alteration in GSC protein expression after radiation could reflect on the surrounding 
microenvironment. A pivotal point could be the effect of this modified microenvironment on 
BBB protein expression and permeability. Hence, conditioned medium (CM) obtained 
culturing irradiated (2Gy) GSCs were added to the transwell BBB models in order to 
recapitulate irradiated microenvironment and compared to non-irradiated (0Gy) CM. Both the 
conditioned medium induced an upregulation of LDLR on hCMEC/d3 cells but only CM from 
irradiated GSCs caused a stable drop of TEER, indicating an increased BBB permeability (Fig 
15 A, B).
Fig. 15: effect of irradiated GSC conditioned medium on BBB. A) TEER values of BBB transwell model untreated 
(CTR) or incubated with GSC conditioned media (CM) before (0Gy) and after radiation (2Gy). B) LDLR protein level in 
hCMEC/D3 cells before (CTR) and after 12h-incubation with CM from non-irradiated and irradiated GSCs. Pairwise 
comparison was performed by Student’s t-test.*P < 0.05, **P<0.01. 
Overall, these results demonstrate the ability of mApoE-DOXO-LIPs to target in vitro 
different patient-derived GSCs biding LDLR. Moreover, the enhanced expression of LDLR 
on GSC cells after irradiation and the overexpression of the receptor on endothelial cell 
induced by GSC CM suggested that mApoE-DOXO-LIPs and radiotherapy could be 
efficiently combined to develop an in vivo protocol. 
1.3 mApoE-DOXO-LIP antitumor activity in orthotopic GSC-PDXs 
The in vitro results strongly suggested that RT may facilitate LIP brain delivery and uptake 
by tumoral cells. Therefore, mApoE-DOXO-LIPs were delivered either as single treatment 
or in combination with radiations to BG003-PDX obtained by orthotopic injection of 
luciferase-transfected BG003 (BG003luc). Injection of human cells in mouse represents a 
great issue since host immune system immediately recognizes tumor cells as non-self and 
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rejects the graft. To overcome tumor cells rejection, BG003luc cells were implanted in 
NOD/SCID mice that have impaired T and B cell lymphocyte development and lack in 
natural killer (NK) cell function. Tumor growth in this model is quite slow. Indeed, it took 
60 days after BG003luc intracranial injection (D60) to detect a visible tumor mass (Fig 16 
B). Starting from D60 mice were treated with mApoE-functionalized LIPs as single agent 
(mApoE-DOXO-LIP) or in combination with radiation (2Gy/mApoE-DOXO-LIP) 
according to the schedule reported in (Fig 16 A). Untreated mice (CTR), and mice treated 
with untargeted LIPs (DOXO-LIP) or radiation only (2Gy) were included as controls. 
BLI performed during (D67) and at the end (D75) of the treatment (Fig. 16 B) indicated an 
overall low tumor growth rate that underwent a considerable boost in the subsequent ten 
days (D85) reaching an 8.4±5.3 and 12.0±8.2-fold increase, in untreated and DOXO-LIP 
controls, respectively. Treatment with mApoE-DOXO-LIP slowed tumor expansion to a 
6.3±2.7 fold increase (Fig. 16 C, D). Importantly, the highest and significant level of tumor 
growth inhibition, -6.4±4.7 times, was observed in mice receiving radiation together with 
mApoE-DOXO-LIPs (2Gy/mApoE-DOXO-LIP) (Fig. 16 B, D). Accordingly, overall 
survival equaled tumor expansion/inhibition, with 2Gy/mApoE-DOXO-LIP treatment 
resulting in increased survival compared to any other treatments (Fig. 16 E). 
Morton and Griffith’s parameters of animal condition (body weight, physical appearance, 
measurable clinical signs, unprovoked behavior and response to external stimuli) (Morton 
and Griffith, 1985) were monitored periodically until the end of the experiment. Body 
weight monitoring indicated a loss of weight, approximately 12%, in all mice receiving 
LIPs. Weight loss stopped in concomitance with the end of the treatment (D75) and since 
then mice started gaining weight regardless tumor volume and death event (Fig. 16 F) 
suggesting a sensible, yet compatible with life, LIP systemic toxicity.  
mApoE-DOXO-LIP biodistribution performed after a single injection in healthy mice with 
radio labelled DOXO and LIPs showed LIPs prolonged DOXO circulation half-life and 
reduced DOXO accumulation in liver, kidney, lungs and hearth (Fig. 16 G, H). 
Nonetheless, the liver remains the main organ where approximately 40-50% of the injected 
LIPs accumulate, probably inducing the systemic suffering and weight loss observed. 
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A progressive increase of DOXO accumulation was detected upon mApoE-DOXO-LIP 
delivery in brain. Results indicated that 24h after injection the amount of free DOXO in the 
brain was reduced by 2.7-fold whereas it was 4.4-fold higher after the administration of 
mApoE-DOXO-LIP (Fig. 16 G). However, low levels of signal were detected in the brain 
suggesting a limited amount of  mApoE-DOXO-LIP could cross intact BBB. 
Fig. 16: in vivo efficacy of mApoE-DOXO-LIPs in the GSC-PDX model. A) Treatments started sixty days (D60) after 
intracranial injection of BG003luc cells and were administered according to the indicated schedule. BG003luc bearing 
mice (n=9 mice/group) received 35 µg/dose of encapsulated DOXO intraperitoneally. Irradiation (2Gy) was administered 
as whole-brain treatment. B) Representative BLI imagines of tumor-bearing mice untreated (CTR), and treated with 
untargeted DOXO-LIPs (DOXO-LIP), mApoE-functionalized LIPs as single agent (mApoE-DOXO-LIP) or concomitant 
with radiation (2Gy/mApoE-DOXO-LIP). C) Time course quantification of tumor BLI signals. Results are expressed as 
mean of radiance values ± SE detected at the indicated time points. P-values are calculated using two-way ANOVA and 
Tukey’s multiple comparisons test (**P < 0.01). D) Tumor growth/inhibition at D85 (12 days after treatment end). Data 
are expressed as relative BLI radiance mean values ± SE normalized to BLI values at D75. E) Kaplan–Meier survival 
curve. P-log = 0.0863. F) Body weights of the alive animals at the indicated time points. Data are presented as the mean 
values ± SE. G) mApoE-DOXO-LIP distribution in peripheral organs and across intact BBB. Dually radiolabeled 
mApoE-DOXO-LIP ([3H]-Sm/[14C]-DOXO) or free-[14C]-DOXO were intravenously injected in healthy mice. Mice 
were sacrificed 3h or 24h after the injection. Radioactivity in peripheral organs was measured by liquid scintillation 
counting. The amount of [3H]-Sm or [14C]-DOXO is expressed as percentage of injected dose (ID) ± SD. Pairwise 
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To examine in depth the tumor growth inhibition in mApoE-DOXO-LIP-treated mice, BLI 
experiments were corroborated by histological analyses. A new group of mice were 
injected with BG003-luc and treated as in the previous experiment (Fig. 16 A). At the end 
of the treatment (D75), brains were collected from sacrificed mice and three section of 
each brain were analyzed (Fig. 17 A). Results confirmed that BG003 cells maintained their 
stemness demonstrated by the expression of the stem markers Nestin and SOX2 (Fig 17 
B). BG003 detected by Human Nuclei (HU) immunohistochemistry in GSC xenograft 
confirmed tumor shrinkage in mice receiving radiation and mApoE-DOXO-LIPs (Fig. 17 
C). In order to obtain an index of tumor growth and progression, BG003 cells were 
counted in the contralateral, not-injected hemisphere. BG003 quantification revealed a 
reduction of tumor cell spreading along commissural fibers upon treatment with radiation 
either alone (2Gy) or in combination with mApoE-LIPs (2Gy/mApoE-DOXO-LIP) as 
indicated by the significant lower number of DAPI/HU-positive cells in the contralateral 
hemisphere (Fig 17 C, D). 
Apoptosis analysis (TUNEL assay) indicated a co-localization between TUNEL and HU 
staining (Fig. 17 C). Notably, apoptotic BG003 cells were observed exclusively in the 
xenografts of mice receiving mApoE-DOXO-LIPs, both as single agent (0Gy/mApoE-
DOXO-LIP) or concomitant with radiation (2Gy/mApoE-DOXO-LIP). No/low TUNEL 
staining was observed in mice treated with radiation alone (2Gy) and in HU-negative 
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Fig. 17: tumor growth and apoptosis in mApoE-DOXO-LIP treated GSC-PDX. Mice (n=4 mice/group) treated as 
previously described (Fig.4A) were sacrificed at D75 and brains collected for histological analyses. A) Three coronal 
brain cryosection (10 μm) were analyzed for each treated and untreated mouse. Cryosection at the intersection of the 
tumor injection site and serial anterior posterior sections (50 mm distance) were considered. Coronal images were 
acquired using a DMi8 fluorescent microscope and a Leica Application Suite X (LASX) imaging system (Leica 
Microsystems). DAPI signal (blue) for nuclei detection was used to delimitate brain section contour (white line). B) 
Representative image of staminal markers nestin (green) and sox2 (red) expression in BG003 xenografts 80 days after 
intracranial injection. In blue is the DAPI signal for nucleus detection. C) Representative coronal sections from untreated 
(CTR) and 2Gy/mApoE-DOXO-LIP treated mice. BG003 cells were detected by anti-human nuclei (HU) 
immunofluorescence. Apoptotic cells were detected by TUNEL staining on the same brain sections. D) Quantification of 
BG003 cells in contralateral, not-injected hemisphere calculated as number of HU+/DAPI+ nuclei with a fixed area range 
of 12-50 mm2. Imaging analysis was carried out using the FIJI software. Results are expressed as mean of HU+/DAPI+ 
nuclei ± SE. E) Quantification of apoptotic cells defined by nuclear HU, DAPI and TUNEL co-localization. Results are 
expressed as mean values ± SE of HU-positive (human, black bars) and HU-negative (murine, white bars) cells. Only 
murine cells in the contralateral hemisphere were considered. Imaging analysis was carried out as in panel B. One-way 
ANOVA and Bonferroni post hoc testing were used to assess differences between treatments, *P< 0.05; **P < 0.01. 
These data confirmed tumor reduction in mApoE-DOXO-LIPs treated mice and the 
adjuvant effect that targeted LIPs have in combined therapy with radiation. Moreover, 
DOXO encapsulation suggested reduced side toxicity on non-humoral cells. 
ICD induced by DOXO on tumor cells should induce the removal of death cells by 
scavenger cells (Werfel and Cook, 2018). In the context of GBM these cells are 
represented by Glioma-Associated Microglia/Macrophages (GAMMs) (Gieryng et al., 
2017). GAMM infiltration was evaluated in the BG003-xenographt by means of Iba1 
immunostaining. No relevant differences were detected in the extent of GAMM infiltration 
among the treatments (Fig. 18 A, B). Conversely, a conspicuous difference in the 
morphology of Iba1-positive cells was observed (Fig 18 B). In untreated tumors, 
infiltrating GAMMs displayed a ramified, highly branched shape disclosing a resting 
status. In contrast, in mApoE-DOXO-LIP treated tumors GAMMs had an amoeboid 
morphology revealing a phagocytic/activated phenotype (Fig. 18 B). Moreover, HU-
positive fragments were visible inside GAMMs of mApoE-DOXO-LIP-treated mice (Fig. 
18 C).  
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Fig. 18: Iba1 cells infiltration in xenograpgt and morphology. A) Quantification of microglia macrophages in brain 
cryosections by Iba1 and DAPI staining detected using a DMi8 fluorescent microscope (Leica Micro systems). Iba1/
DAPI-positive cells present in the tumor-injected hemisphere were counted in three serial section for each brain (Fig. 11 
A). Quantification was carried out by imaging analysis (FIJI software). Results are expressed as mean values±SE of at 
least nine sections of the indicated treatment group. B) Representative images of cryosectons in the tumoral area from 
untreated mice (CTR) and animals treated with radiation (2Gy), DOXO-LIPs or mApoE-DOXO-LIPs alone (0Gy)or 
incombination withradiation (2Gy). 
Of note, GAMM amoeboid morphology and HU-positive fragments co-localized with 
TUNEL staining (Fig. 19 B), indicating GAMM-mediated phagocytosis of cellular/nuclear 
debris released by apoptotic BG003 cells. As a further support, Iba1-positive cells 
associated to vital TUNEL-negative BG003 cells had a branched morphology and an intact 
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To further demonstrate that LIP-encapsulated DOXO can trigger ICD, CD11 expression 
was analyzed as marker of antigen presentation (Hume, 2008) in GAMM of BG003-
xenographt. No CD11c induction was detected in resting microglia/macrophages from both 
untreated and irradiated mApoE-DOXO-LIP-treated mice, whereas CD11c was 
upregulated in activated GAMM upon mApoE-DOXO-LIP/radiation combined treatment 
(Fig. 19 C). 
Fig. 19: immune activation in GSC xenografts. A) Representative 3D images of Iba-positive, tumor infiltrating 
microglia/macrophage in untreated (CTR), irradiated (2Gy) and mApoE-DOXO-LIP, without (0Gy) and with (2Gy) 
radiation, treated mice. Yellow staining indicates HU and Iba1 co-localization. B) In situ TUNEL detection within Iba1-
positive cells at tumor border. C) Representative confocal images of CD11c (white) immunohistochemical detection in 
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These in vivo results demonstrate the ability of the mApoE peptide to efficiently target 
both the BBB and the GSCs leading to a reduced tumor growth and cellular dissemination 
in the healthy parenchyma. Reduced tumor growth and cellular dissemination could be the 
cause of the prolonged overall survival shown in the mice group treated with the combined 
treatment 2Gy + mApoE-DOXO-LIPs. Notably, this treatment seems to activate the 
immune system through the ICD induced on the tumor cells, suggesting a possible 
enhancement of the response against the tumor in an immune competent organism. 
However, a considerable treatment toxicity was observed. LIPs treated mice experienced a 
body weight loss of approximately 12%. Since the observed systemic toxicity could 
endanger the feasible use of LIPs as nano-carrier for GBM treatments, a more specific and 
less toxic system need to be tested in order to achieve the reduction of the treatment 
toxicity prefixed in the rationale of this  thesis. 
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2. MMP2-activatable polymeric nanovectors to reduce toxicity 
Despite the positive results, mApoE-targeted, DOXO-loaded LIPs were able to fulfill only 
the following prefixed features: 
1. BBB crossing aptitude 
2. selectivity to GSCs  
3. Activation of surrounding microenvironment 
However, the excessive weight loss shown in the in vivo experiments suggests a systemic 
toxicity also due to the scaffold since the weight loss was registered in all the group treated 
with the LIPs, both conjugated or not. Therefore, in order to reduce the treatment toxicity, a 
different delivery system based on polymer technology was investigated. 
Polymer are FDA approved materials used in nanoparticle synthesis.. Polymeric NPs are 
considered less toxic compared to LIPs (Sharma et al., 2012) and, moreover, polymers are 
a more versatile material (Rideau et al., 2018). These two aspect make polymeric NPs an 
optimal biocompatible scaffold in order to create efficient and safe targeted nanosystems. 
Different type of polymer used to create NPs including poly(lactic-co-glycol acid) 
(PLGA), poly(ε-caprolactone) (PCL) the most used and characterized polymer to 
synthesized NVs. 
As mApoE exerts no/limited activity on the cells present in the surrounding tumor 
microenvironment, in order to increase GBM specificity, NP functionalization was 
implemented I with a MMP2/9 activatable strategy. Indeed, the activatable system was 
created by fusing a Low Molecular Weight Ptoramine (ALMWP) with an inhibitory 
sequence spaced by a MMP2/9 sensitive peptide (see Fig. 9). The presence of high level of 
MMP2/9 in the GBM microenvironment should assure the correct activation of the NPs 
only near the tumor, reducing the uptake by other cells in particular scavenger one. 
The polymer chosen to create the implemented system was PLGA, a well characterized 
and known materials (Sharma et al., 2012; Rideau et al., 2018) and was conjugated with 
the MMP-activatable sequence. The  synthesis and characterization of the NPs was 
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conducted in prof Cellesi’s lab at the department of Chemistry, Materials and Chemical 
Engineering “Giulio Natta” (CMIC), Politecnico of Milan. 
2.1 Characterization and selection of MMP-expressing GSC lines 
GSCs with similar sensitivity to DOXO and different MMP2 enzymatic activity were 
designated as suitable cellular model for the development of GBM specific activatable 
nanovectors. Patient-derived GSC primary lines present in the laboratory’s collection (see 
methods section) were tested for MMP2 expression and activity by real-time PCR, western 
blot and zymography. Among the cell lines available ICH001, ICH003 and ICH013 GSC 
lines were selected. The selected cell lines displayed similar cellular response to DOXO 
(Fig 20 A) and equivalent amount of MMP2 mRNA (Fig. 20 B). Interestingly, while 
ICH013 GSCs showed the lowest amount of MMP2 protein level, a higher enzymatic 
activity was observed in ICH013 supernatant compared to ICH001 and ICH003 ones (Fig. 
20 C, D).  
Fig. 20: GSCs drug sensitivity and MMP2 activity. A) Free DOXO responsiveness of ICH001, ICH003 and ICH013 
determined by MTT viability assay after 48h incubation at increasing drug concentration. Values are expressed as 
percentage of untreated cells. B) MMP2 mRNA levels determined by real time PCR. Values are expressed as the mean of 
at least 4 technical replicates normalized on GAPDH mRNA expression. C) MMP2 protein amount determined  by 
western-blot. D) MMP2 enzymatic activity detected in 24h cell culture supernatant and assay by zymography. Values are 
expressed as the mean ± SE of three independent experiments. 
2.2 PLGA / poly(ethylene glycol) (PEG) copolymer 
Due to their high biocompatibility PLGA and PEG are polymers approved by Food and 
Drug Administration (FDA) and European Medicines Agency (EMA) and therefore 
employed in various drug delivery systems (Rideau et al., 2018). DOXO-loaded, MPP-
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PLGA and amino-PEG-acid. The resulting copolymer was further functionalized with a 
maleimide group, to obtain the PLGA-PEG-MALE polymer. The PLGA-PEG-MALE was 
conjugated with a cysteine-terminated LMWP or ALMWP peptide through a Micheal-type-
addition. Finally, DOXO was encapsulated by standard nanoprecipitation (Fig. 21 A). 

NVs size distribution was evaluated before and after DOXO encapsulation by nanoparticle 
tracking analysis (Fig. 21 B) using a NS300 NanoSight (Malvern Panalytical, Malvern, 
UK), showed NVs uniform diameter size of about 130 nm, negative Z-potential and 
Polydispersity Index (PDI) lower than 1 (Fig. 21 B, C). 
To demonstrate that the observed cytotoxic effect was due to embedded DOXO and not to 
nanovector polymeric core itself, a viability assay was carried out with unloaded, non-
encapsulated DOXO, empty nanovectors (Fig. 21 D). As expected, the results showed no 
inhibition of GSC viability caused by polymeric scaffold. Differently, an increasing dose-
dependent toxicity, up to 60% reduction of cell viability, was observed upon GSCs 
incubation with LMWP and ALMWP decorated empty nanovectors.  Nevertheless, these 






















Averaged FTLA Concentration / Size for Experiments:
WH106 filtrato hum 2019-03-01 14-32-58, WH107 filtrato hum 2019-03-01 15-04-36, WH108 filtrato hum 2019-03-01 14-02-44
Error bars indicate + / -1 standard error of the mean
Concentration Values (particles / ml):
Experiment: WH106 filtrato hum 2019-03-01 14-32-58.nano
Concentration: 5.10 E8
Experiment: WH107 filtrato hum 2019-03-01 15-04-36.nano
Concentration: 6.35 E8
Experiment: WH108 filtrato hum 2019-03-01 14-02-44.nano
Concentration: 6.80 E8
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14035 70 280 0 14035 70 280
ALMWP-PLGA-PEG
NV formulation Size (nm) Z-Potential (mV) PDI
PLGA-PEG 128±33 -16 0.1
DOXO-PLGA-PEG 106±39 -12 0.156
LMWP-PLGA-PEG 135±36 -4 0.2
LMWP-DOXO-PLGA-PEG 130±43 -7 0.197
ALMWP-PLGA-PEG 138±37 -16 0.2
ALMWP-DOXO-PLGA-PEG 116±46 -12 0.134
D
Fig. 21: ALMWP-DOXO-PLGA-PEG synthesis and characterization. A) PLGA-PEG nanovectors synthesis and 
DOXO encapsulation. B) Representative nanovectors signal obtained by light scattering at NanoSight NS300 and 
representative NVs size distribution determined by NTA analysis. C) Mean size !"SD, Z-potential and PDI of empty and 
DOXO loaded PLGA-PEG nanovectors. Parameters were obtained after 3 repetition in ultra pure water. Data kindly 
provided by prof Cellesi’s lab D) Cell viability assayed by MTT test after 48 h incubation with unloaded, not 
encapsulating DOXO empty nanovectors. Values are expressed as mean percentage survival of 4 technical replicates"!"
SE normalized to the corresponding values of untreated GSC cultured without nanovectors. 
As MMP production in and NV activation are time-dependent and connected events, real-
time cellular uptake/internalization driven by ALMWP cleavage was investigated in 
ICH001, ICH003 and ICH013 GSC lines by cell microscopy and imaging (DMi8 
microscope and LAS-X software, Leica) (Fig. 22). 
Three different NVs formulation were tested: 
1) DOXO-PLGA-PEG without any external decoration but encapsulating DOXO;  
2) LMWP-DOXO-PLGA-PEG nanovectors functionalized with active CPP peptide; 
3) ALMWP-DOXO-PLGA-PEG nanovectors funtionalized with MMP2-activatable 
CPP peptide. 
Nuclear DOXO quantification showed no difference in the uptake rate of ALMWP-
DOXO-PLGA and LMWP-DOXO-PLGA that is consistently higher than not-
functionalized nanovectors. 
Overall, nuclear DOXO quantification showed a time dependent cellular uptake and 
internalization rate more manifest when GSCs were incubated with CPP-functionalized 
(LMWP-DOXO) and MMP2-activatable (ALMWP-DOXO) nanovectors (Fig. 22 B). Both 
LMWP-DOXO and ALMWP-DOXO-PLGA nanovectors displayed a similar degree of 
internalization that was mostly higher compared to non-decorated control nanovector. No 
consistent differences were observed between GSCs with low (ICH001, ICH003) and high 
(ICH013) MMP2 activity (Fig 20 D, Fig 22 B). Therefore, despite these results suggest 
that the ALMWP-peptide can efficiently work in the presence of GSCs, an MMP 
dependent activation was not indicated. 
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More importantly, after a 10 hour incubation with DOXO-PLGA-PEG nanovectors, cell 
nuclei were visibly engulfed by DOXO (Fig 22 A) and no significant difference in nuclear 
DOXO accumulation were detected (Fig. 22 B), suggestive of a passive and uncontrol 
DOXO internalization due to nanovector drug release. A fast (starting from 4-5 hours of 
incubation) drug release is reminiscent of a probable non-specific, off-target cytotoxic 
effect that would restrain the advantages of a targeted delivery system. Indeed, cell 
viability assay performed at 24 and 48 h incubation in the presence of increasing 
concentration of nanovectors/DOXO indicated the lack of significant differences in cell 
death among nanovectors, including the untargeted DOXO-PLGA negative control (Fig. 
23). 
Fig. 22: DOXO-PLGA nanovectors live imaging uptake.  GSCs were incubated with nanovectors at a [DOXO] of 4µg/
ml. One images per hours was capture by real-time microscopy. A) Representative images of ICH001 cells incubated 
with the indicated nanovectors showing DOXO (red) inside the cells. DAPI was used for nuclear staining. The right panel 
shows te bright-field differential interference contrast merged signals. B) Real-time nuclear DOXO quantification 
expressed as Integrated Density (Int. Den) ± SE in ICH001, ICH003 and ICH013 GSC patient-derived cell lines 
incubated with the indicated PLGA-PEG-DOXO nanovectors (0-10 h, [DOXO] 4 µg/ml) in 3 independent experiments. 


















































   



















































After 24h incubation, both decorated and undecorated nanovectors induced the same cell 
viability reduction (Fig 23). Unfortunately, also the negative control reaches the same % of 
cell viability, except on the ICH001. After 48h all nanovectors were able to kill more than 
50% of cells at the lower concentration of encapsulated DOXO (1,25 µg/ml) considered 
(Fig. 23). Interestingly, these results are comparable to those obtained by incubating the 
GSCs with the same quantity of free DOXO supporting that embedded DOXO released by 
nanovectors enter the GSC and acts as free DOXO (Fig. 19 A). 
Fig. 23: viability assay on GSCs treated with DOXO-PLGA nanovectors.  Cell viability assayed by MTT test after 24 
and 48h incubation with the indicated nanovectors and [DOXO]. Values are expressed as mean percentage survival of 4 
technical replicates"!"SE normalized to the corresponding values of untreated GSC cultured without nanovectors. 
Overall, these results are consistent with an overtime DOXO release from the PLGA-PEG 
polymeric core. In a recent publication, Malinovskaya et al. reported that PLGA-based 
nanovectors passively released nearly 50% of the encapsulated DOXO after 6 hours at pH 
7.4 (Malinovskaya et al., 2017). Uncontrolled release of DOXO represents a great concern 
and setback to the translation of DOXO-loaded PLGA-based nanovectors in the clinic. 
Therefore, due to the failure of drug retention and the consequent toxicity, in accordance 
with the engineers, we decided improve the material and polymer structure for the 









































2.3 Star-shaped PCL-PEG based nanovector 
As the attempts to ameliorate DOXO-entrapping into PLGA did not produce suitable 
results, PLGA-PEG nanovectors were substituted with novel nanovectors obtained by self-
assembly of an alternative star-shape PCL based macromolecules. PCL was selected to 
enhance the hydrophobicity of the nanovectors core, aiming to improve stability and drug 
retention (Kommareddy et al., 2005). The star-shaped PCL-PEG brush architecture was 
designed for a better control of nanoparticle self-assembly and functionality in term of 
peptide grafting and presentation.  
As PCL could better retain DOXO inside the PCL core, the uptake analysis should better 
discriminate the nuclear DOXO amount of NVs decorated with CPP compared to PCL-
PEG-DOXO. Moreover, the star-shape and the multi-functionalized brushes should reduce 
the time that NVs needs to interact with the cells. 
Star-shaped multifunctional PCL-PEG copolymers were synthesized through controlled 
polymerization of PCL- and PEG- based macromonomers, using 4-arm PCL-based 
macroinitiators. The copolymers were further acrylated and functionalized via Michael 
type addition with the active peptides (LMWP, ALMWP). DOXO was finally encapsulated 
by a standard nanoprecipitation method (Fig 24 A).  
Nanovectors size distribution was evaluated before and after DOXO encapsulation. NTA 
showed a uniform diameter size of about 90-100 nm. DOXO encapsulation didn’t 
significantly changed the size of the nanovectors (Fig. 24 B, C). Functionalized 
nanovectors showed a negative Z-potential while untargeted, both loaded and unloaded, 
has positive Z-potential (Fig 24 C). PDI was always lower than 1 (Fig 24 C).

Viability assay performed with empty nanovectors showed a 40% viability reduction in 
GSCs treated with undecorated and LMWP decorated nanovecrtors. Differently, ALMWP 
decorated nanovector was the most safe formulation with a 10-15% viability reduction 
depending on GSCs (Fig. 24 D). 
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Fig. 24: synthesis and characterization loaded PCL-PEG based nanovectors . A) Schematic representation of PCL-
PEG nanovector synthesis, peptide functionalizastion and DOXO encapsulation. B) Representative image of nanovectors 
light scattering obtained by NanoSight (Malvern Panalytical). C) Representative NVs size distribution and concentration 
obtain by NTA. Data kindly provided by prof Cellesi’s lab D) Mean size and Z-potential of each different PLGA-PEG 
NVs, both empty and DOXO loaded. Parameters were obtained in ultra-pure water. E) Cell viability assayed by MTT test 
after 48 h incubation with unloaded, not encapsulating DOXO empty nanovectors. Values are expressed as mean 
percentage survival of 4 technical replicates ± SE normalized to the corresponding values of untreated GSC cultured 
without nanovectors.

Three different PCL-PEG nanovectors formulation were investigated:  
1) DOXO-PLGA without any external decoration but encapsulating DOXO;  
2) LMWP-DOXO-PLGA nanovectors functionalized with active CPP peptide; 














































Averaged FTLA Concentration / Size for Experiments:
wh118LMWP 1-100 2019-05-23 11-31-30, wh119ALMWP 1-100 tris 2019-05-23 12-26-27, wh120polymer 1-100 2019-05-23 12--
13-10
Error bars indicate + / -1 standard error of the mean
Concentration Values (particles / ml):
Experiment: wh118LMWP 1-100 2019-05-23 11-31-30.nano
Concentration: 6.87 E8
Experiment: wh119ALMWP 1-100 tris 2019-05-23 12-26-27.nano
Concentration: 3.64 E8






















































50 1002512 0 50 1002512 0 50 1002512
D
NV formulation Size (nm) Z-Potential (mV) PDI
PCL-PEG 103,2±37 10 0.238
DOXO-PCL-PEG 148±25 14 0.734
LMWP-PCL-PEG 105,5±34 -13 0.771
LMWP-DOXO-PCL-PEG 105.7±14 -9 0.698
ALMWP-PCL-PEG 128.2±18 -23 0.713
ALMWP-DOXO-PCL-PEG 93,7±13 -20 0.297
Fig. 25: PCL-PEG NVs live imaging uptake.  GSCs were plated and treated with NVs at a [DOXO] of 1,2µg/ml. One 
images per  hours was capture for each well by DMi8 microscope (Leica). A) Representative live microscopy images of 
ICH013 cells incubated with the indicated nanovectors for 7h showing DOXO (in red) inside the cells. DAPI was used 
for nuclear staining. The right panel shows three bright-field differential interference contrast merged signals. B) Real-
time nuclear DOXO quantification expressed as Integrated Density (Int. Den) ± SE in ICH001, ICH003 and ICH013 
GSC patient-derived cell lines incubated with the indicated PCL-DOXO nanovectors (1-5h, [DOXO] 1,2 µg/ml). Images 
were analyzed by LAS-X software (Leica). Nuclear DOXO amount was quantify in 90-100 cells per time point in one 
experiment. C) Comparison of ALMWP-DOXO-PCL uptake between the three GSC lines analyzed in panel B. Pairwise 
comparison was performed by Student’s t-test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
Likewise PLGA-PEG nanovectors, incubation with DOXO-loaded PCL-PEG nanovectors 
triggered  a time-dependent nuclear DOXO accumulation in all three GSC lines 
considered. However, differently from PLGA-PEG nanovectors, significant DOXO 
accumulation was promptly observed with MMP-activatable (ALMWP-DOXO-PCL) and 
CPP-decorated (LMWP-DOXO-PCL) compared to non.functionalized (DOXO-PCL) 
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DOXO nuclear accumulation in patient-derived GSCs. A) Representative live microscopy images of ICH001 cells incubated with the indicated 
nanovectors showing  DOXO (in red) inside the cells. DAPI was used for nuclear staining. The right panel shows te bright-field differential interference 
contrast merged signals. B) Real-time nuclear DOXO quantification expressed as Integrated Density (Int. Den) ± SE in ICH001, ICH003 and ICH013 GSC 
patient-derived cell lines incubated with the indicated PCL-DOXO nanovectors (1-5h, [DOXO] 1,2 µg/ml). Pairwise comparison was performed by 
Student’s t-test. ***P<0.001, ****P<0.0001. At least 100 cells per time point were analyzed.
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Association of MMP2 proteinase activity and nanov ctor cellular uptake. A) Quantificatio  of MMP2 activity assayed by zymography in the co itioned 
medium (24 hours) of ICH001, ICH003 or ICH013 cells. Band intensity was measured after comassie staining by ChemiDock (BioRad) B) Real-time nuclear 
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nanovectors starting from one hour incubation and at a lower DOXO concentration (1,2 vs 
4 µg/ml) (Fig. 25 A, B). 
A different magnitude of nuclear DOXO level was observed among the GSCs after 
ALMWP-DOXO-PCL- incubation with ICH013 showing the highest level of DOXO 
accumulation (Fig. 25 C). Importantly, ICH013 highest level of DOXO accumulation 
correspond to their highest MMP2 activity (Fig. 20 D) suggesting a positive correlation 
between ALMWP nanovectors activation and level of MMP2. 
These results suggested that the star-shaped PCL-PEG scaffolds could effectively better 
retain DOXO into the nanovector core compared to PLGA-PEG one and that the 
activatable peptide could be cleaved by GSC MMPs exposing the CPP allowing targeted 
DOXO-PCL nanovector enter the cells. Moreover, the corresponding level of MMP2 
activity and ALMWP-DOXO-PCL cellular uptake supported the crucial involvement of the 
MMP2 enzymatic activity in the activation of the ALMWP nanovector.  
Viability assay enforced these observations showing significant differences among 
decorated and undecorated nanovectors. ALMWP-DOXO-PCL significantly reduced 
viability compared to DOXO-PCL in ICH001 and ICH003, 40% and 45% respectively, 
comparable to LMWP-DOXO-PCL positive control. ICH013 seemed to be more sensible 
to both undecorated and decorated nanovectors. Nevertheless, ALMWP-DOXO-PCL 
showed a 50% viability reduction compared to both DOXO-PCL negative control and 
LMWP-DOXO-PCL positive control, suggesting that the ALMWP nanovectos higher 
uptake observed (Fig. 25 A, B) effectively reflected a higher toxicity (Fig 26). 
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Fig. 26: viability assay. Cell viability assayed by MTT test on ICH001, ICH003 and ICH013 with the indicated 
nanovectors at [DOXO] of 0,6 µg/ml. Values are expressed as mean percentage survival of 4 replicates ± SE normalized 
to corresponding untreated cells. Pairwise comparison was performed by Student’s t-test. *P<0.05,**P<0.01. 
To better characterize ALMWP-DOXO-PCL, its toxicity was assayed at different 
concentration (0,6 vs 1,2 µg/ml) and time point (48 vs 72h). In all the GSCs, ALMWP-
DOXO-PCL induced a significant dose response halving cell viability (Fig. 27). Moreover, 
in ICH003 and ICH013 ALMWP nanovector significantly induced a time dependent 
viability reduction (Fig. 27). No time dependent viability reduction was observed in 
ICH001. 
Fig. 27: ALMWP-DOXO-PCL dose response/time dependent viability assay. A) Cell viability assayed by MTT test 
after 48 and 72h incubation with ALMWP-DOXO-PCL at [DOXO] of 0,6 or 1,2 µg/ml. Values are expressed as mean 
percentage survival of 4 repetitions ± SE normalized to corresponding untreated cells cultured without nanovectors. 
Pairwise comparison was performed by Student’s t-test. *P<0.05,**P<0.01, ***P<0.001 
To further demonstrate that the cell entry to the activatable nanovectors was due to MMPs 
and, at the same time, that nanovectors were non-toxic to non-tumoral cells, ALMWP-
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Nanovector Cytotoxicity in GSCs cells. Cell viability assayed by MTT test after 72h incubation with the indicated 
nanovectors at [DOXO] 0,6 µg/ml and [DOXO] 1,2 µg/ml just for PCL-ALMWP-DOXO. Values are expressed as mean 
percentage survival of six repetitions ± SE normalized to corresponding untreated cells coultivated without nanovectors. 









































































DOXO-PCL uptake was investigated in hCMEC/d3 human endothelial cell line that does 
not express MMP2 (Fig. 28 A).  
As expected, results clearly showed that, opposite to GSC lines, endothelial cells displayed 
the highest DOXO uptake upon exposure to the LMWP-DOXO-PCL (CPP-targeted 
positive control) and the lowest one upon MMP2-acyivatable ALMWP-DOXO-PCL 
nanovectors. ALMWP-DOXO-PCL did not enter hCMEC/d3 cells and nuclear DOXO 
signal was comparable to the one of the cells incubated with untargeted DOXO-PCL 
(negative control) (Fig. 28 B, C). 
Consequently, as only the active CPP peptide could interact directly with the hCMEC/d3 
cell membrane, LMWP-DOXO-PCL resulted the most toxic nanovectors while ALMWP-
DOXO-PCL treated cells showed a significant 70-80% survival rate equivalent to 












   







   









































































ICH001 ICH003 ICH013 hCMEC/d3A
Fig. 28: uptake and viability assay on hCMEC/d3 to verify MMP2 involvement in NVs internalization and toxic 
effect. A) Representative image of MMP2 protein amount in endothelial cells compared to GSCs. Image acquired by 
ChemiDock (BioRad). B) Representative confocal images of human endothelial cells (hCMEC/d3) after 5-hour 
incubation with indicated PCL-DOXO nanovecors, [DOXO] 1,2 µg/ml. In blue is the Hoechst signal for nucleus 
detection and in white is Phalloidin for cell body detection. C) Nuclear DOXO quantification expressed as Integrated 
Density (Int. Den) ± SE in cells incubated with PCL-DOXO nanovectors as indicated (6h, [DOXO] 1,2 µg/ml). At least 
300 cells per condition were analyzed. D) Cell viability detected by MTT assay after 24h incubation with the indicated 
nanovectors at [DOXO] 0,6 µg/ml. Values are expressed as mean percentage survival (for replicates ± SE) normalized to 
corresponding untreated. Pairwise comparison was performed by Student’s t-test. **P<0.01***P<0.001, ****P<0.0001. 
Taken together these results confirm that ALMWP-DOXO-PCL nanovectors efficiently 
targets GSCs, due to their high MMP2 expression and release in the surrounding 
microenvironment. The specificity of the MMP2 dependent activation has been 
demonstrated by the inability of the endothelial cells that do not express MMP2 and, 
consequently, did not activate the nanovector. Moreover, the reduction of encapsulated 
DOXO amount (from 10 µg/ml to 1,2 µg/ml) to efficiently affect GSCs viability represents 
a further step forward to the possibility to reduce the treatment related toxicity. Indeed, not 
only the PCL is considered a less toxic scaffold respect the LIPs (Sharma et al., 2012) but, 
moreover, they display higher efficiency compared LIPs to vehicle encapsulated DOXO 
into GSCs allowing to reduce the amount of the administered drug.  
3. mApoE-DOXO-PCL vs mApoE-DOXO-LIP 
To confirm the observation that star-shaped PCL nanovectors are more efficient in drug 
delivery compared to LIPs, a direct comparison of the two system was investigated. 
To uniform the DOXO-loaded PCL and LIP platforms, the mApoE peptide, crucially 
required for BBB crossing but never investigated on PCL-based nanovectors, was chosen 
as surface functionalization. 
The nuclear DOXO uptake determined by live imaging confirmed the higher efficacy of 
mApoE-PCL to be internalized into the cell (ICH001) within 3h incubation, while mApoE-
LIP was even undetectable (Fig. 29 A, B). Consequently, after 72h incubation mApoE-PCL 
significantly induced viability reduction on ICH001 compared to mApoE-DOXO-PCL 
(Fig. 29 C). Moreover, mApoE-DOXO-PCL seemed to induce a dose response as DOXO 




Fig. 29: mApoE-DOXO-PCL vs mApoE-DOXO-LIP uptake and viability assay on GSC. A) Real-time nuclear 
DOXO quantification expressed as Integrated Density (Int. Den) ± SE in ICH001 cells incubated with the indicated 
nanovectors (1-3h, [DOXO] 1,2 µg/ml). Images were analyzed by LAS-X software (Leica). Nuclear DOXO amount was 
quantify in 90-100 cells per time point. B) Representative confocal images of ICH001 cells after 5-hour incubation with 
indicated nanovecors, [DOXO] 1,2 µg/ml. In blue is the DAPI signal for nucleus detection and in white is Phalloidin for 
cell body detection. C) Cell viability detected by MTT assay after 72h incubation with the indicated nanovectors at 
[DOXO] of 0,6 and 1,2 µg/ml. Values are expressed as mean percentage survival (for replicates ± SE) normalized to 
corresponding untreated. Pairwise comparison was performed by Student’s t-test. *P<0.05, **P<0.01,***P<0.001, 
****P<0.0001. 
This preliminary experiment strongly suggests that PCL nanovectors independently from 
GSCs targeting  functionalization are more efficient in GSCs targeting since they can work 
at a lower DOXO concentration compared to LIPs. 
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The goal of this thesis was to generate a drug delivery system able to reach three crucial 
points of GBM treatment development: 
1. BBB crossing aptitude 
2. selectivity to GBM that includes GSCs and surrounding microenvironment 
3. Reduced drug toxicity 
The first attempt to satisfy these points was the mApoE-DOXO-LIPs synthesized by 
NANOMIB at the University of Milano-Bicocca. Results indicated a crucial role of 
mApoE not only to deliver drug-loaded nanovectors across BBB but, importantly, also to 
GSCs. DOXO nuclear accumulation occurred only in the presence of mApoE-
functionalized LIPs and was significantly inhibited by the incubation with endocytosis 
inhibitors, thus indicating a receptor-mediated targeted delivery. In irradiated (2Gy) GSCs 
the higher level of LDLR expression was associated with an increased cellular 
internalization of mApoE/DOXO/LIPs further supporting an mApoE/LDLR specific 
mechanism of cell entry associated to mApoE-functionalized nanovectors. 
The in vivo experiments performed in GSC-PDX demonstrated that despite mApoE-
DOXO-LIPs cross the BBB and target GSCs yet their accumulation and diffusion into the 
brain parenchyma did not reach an adequate tissue concentration to cause a satisfactory 
therapeutic effect. Highest and significant level of tumor growth inhibition associated with 
increased overall survival was observed only in mice receiving radiation together with 
mApoE-DOXO-LIPs (2Gy/mApoE-DOXO-LIP). A dose as low as 2Gy is sufficient to 
modulate LDLR expression and BBB permeability allowing effective liposomal DOXO 
delivery and GSC cell death commitment by apoptosis. Importantly, GSCs death by 
apoptosis seems to activate the ICD and the consequent recruitment of the resident immune 
cell. The over expression of CD11c suggests that the Iba1+ cells (macrophages and 
microglia) could act as presenting cell after ICD activation 
Moreover, in vivo biodistribution indicated that healthy BBB allowed a modest 
accumulation of mApoE-DOXO-LIPs. A low crossing rate through intact BBB combined 
to a higher delivery rate in the irradiated field, would confer tumor tissue selectivity to 
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mApoE-conjugated and drug loaded nanovectors protecting healthy brain parenchyma 
from off-target effects. 
In the last years some LIPs have been approved for clinical applications in oncology 
(Marchal et al., 2015; Wicki et al., 2015). Among them, liposomal DOXO (i.e. Caelyx® or 
Doxil®) is currently used in different protocol of tumor treatment (Zhao et al., 2017). 
However, it failed to be effective against GBM because it can’t cross the BBB (Menei et 
al., 2005; Beier et al., 2009; Ananda et al., 2011). The results of this thesis have 
demonstrated that the mApoE conjugation can  overcome the limitation of the older 
formulation of liposomal DOXO conferring two fundamental aptitudes: 
1. BBB crossing aptitude 
2. selectivity to GBM that includes GSCs and surrounding microenvironment 
These improvements are essential to create a more safe and precise system to target and 
finally treat GBM. Nevertheless, the protocol used in in vivo experiments underlines the 
presence of a pitfall in this system: all mice receiving DOXO-loaded LIPs experienced a 
loss of weight of approximately 12% of the body mass. Weight loss stopped following the 
end of the treatment. Thereafter, mice gained weight regardless tumor volume and death 
event suggesting a sensible DOXO-LIP systemic toxicity. mApoE-DOXO-LIP 
biodistribution indicated that, despite encapsulation significantly reduced DOXO 
accumulation in the principal peripheral organs (liver, kidney, lung, heart), the liver 
remains the main organ where approximately 40-50% of the injected LIPs accumulate. 
Therefore, despite the good results obtained with mApoE-DOXO-LIPs, a more efficient 
systems was needed to reduce treatment toxicity. 
The advantages of using MMP-activatable CPP-functionalized nanocarriers to tackle GBM 
stay in the possibility to improve simultaneously tumor specificity and cell penetrance, 
thus limiting off-target effects. MMP overexpression is a key feature of the tumor 
environment (Egeblad and Werb, 2002) and, moreover, the occasional occurrence of the 
activating conditions in normal tissues supports the applicability of MMP-activatable 
strategies. The multiple and non-selective mechanisms of cellular entrance engaged by 
CPPs to drive the cargo inside the cells make them a powerful and efficient tool to target 
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not only tumoral cells but also the surrounding microenvironment. Moreover, weight loss 
observed also in mice treated with untargeted DOXO-LIPs indicated a systemic toxicity 
caused by the liposome scaffold itself.  Hence, to ameliorate both drug pharmacokinetic 
and pharmacodynamic, it appeared necessary to investigate alternative nanovector 
formulations based on biocompatible nanomaterial, such as polymers, combined to a more 
tumor specific functionalization. 
The first attempt with ALMWP-DOXO-PLGA failed to achieve the expected results. The 
extremely fast DOXO release from the core avoid the possibility to have a target and 
incapsulated system, making the treatment a free DOXO administration. Therefore, a 
different and innovative star-shaped ALMWP-DOXO-PCL was selected for the in vitro 
characterization. 
A different magnitude of nuclear DOXO accumulation was observed after GSC incubation 
with activable ALMWP-DOXO-PCL nanovectors. Consistent with the higher MMP2 
activity, ICH013 cells displayed highest and faster nanovector internalization and higher 
cell viability inhibition upon incubation with activable ALMWP-DOXO-PCL compared to 
active penetrating LMWP-DOXO-PCL nanovector. A dose- and time-dependent DOXO 
cytotoxicity and inhibition of cell viability was observed by culturing GSCs in the presence 
of the activable ALMWP-DOXO-PCL nanovector at increasing dose of DOXO and/or time 
of incubation. Conversely, and as expected, at the same DOXO concentration, no/low 
DOXO internalization and cytotoxic effect  was observed in hCMEC/d3 non-tumoral 
endothelial cells not expressing MMP2 confirming the requirement of MMP2 enzymatic 
activity for ALMWP nanovector activation. As MPP activity level determines the success 
of the activatable nanocarrier, this result indicates that the link of a low molecular weight 
protamine with cell penetrating properties to a MMPs-sensitive sequence is a feasible 
tumor-targeting strategy for GBM. 
The star-shaped PCL-PEG brush architecture was designed for a better control of 
nanovector self-assembly and functionality including peptide grafting. Notably, equivalent 
viability impairment was achieved incubating GSC with ALMWP-DOXO-PCL 
nanovectors at approximately 10 times lower concentration of embedded DOXO compared 
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to mApoE-DOXO-LIPs, 1,2 vs 10 µg/ml respectively. This is possible because the 4-arms 
with terminal “brushes” of star-shaped nanovectors allow a larger number of 
functionalizations per chain as compared to the linear and spheric structures, and, 
consequently, a higher frequency of CPP/cell membrane interactions. 
These results were confirmed by the direct comparison of LIP and PCL nanovectors both 
functionalized with mApoE. mApoE-DOXO-PCL effectively increase the efficacy of 
DOXO delivery respect mApoE-DOXO-LIP at very low DOXO concentration, enforcing 
the hypothesis that 4-arms polymeric core is a more efficient drug delivery system respect 
liposome. Nevertheless, viability reduction induced by mApoE-DOXO-PCL was lower 
respect ALMWP-DOXO-PCL, suggesting that the activatable CPP is actually a better 
targeting functionalization. 
Taken together, the results clearly answer to the aims of the thesis since they demonstrate 
that: 
1. Functionalized NVs are able to deliver drugs that normally don’t cross the 
BBB to brain parenchyma 
2. mApoE and MMP2-activable NVs could efficiently target different GSCs 




Current standard of care is not successful in delivering effective and persistent treatments 
to GBM. Several elements contribute to therapy failure, including the high amount of 
chemo-, radio-resistant tumor-initiating GSCs and the presence of intact BBB in the 
peripheral niches (Geraldo et al., 2019). An effective help can be given by nano medicine. 
By combining passive and active targeting strategies, nano-based drug delivery systems 
can provide better penetration of therapeutics within the cancerous tissue in comparison to 
conventional cancer therapies while avoiding toxicity in healthy cells. Thus, nanocarriers 
can be used for strategic development of novel drug delivery systems and reformulating 
existing drugs to enhance effectiveness. Several drug delivery nanosystems, in particular 
nanoparticles, are currently undergoing advanced clinical trials or, as in the case of 
liposomes (LIPs), have been approved for clinical applications in oncology (Marchal et al., 
2015; Wicki et al., 2015). However, the current approved untargeted liposomal formulation 
failed to be effective against GBM due to the presence of the BBB and for the lack of 
specificity for GBM cells, in particular the infiltrating GSCs (Lathia et al., 2015). 
To cope with the limited and inefficient delivery of chemotherapeutic to the brain, LIPs 
surface-functionalization with the mApoE peptide were investigated as NVs to deliver 
DOXO to the brain and target GSCs. The results obtained demonstrate that the mApoE 
functionalization confer to LIPs the ability to efficiently cross the BBB and target GSCs in 
PDX mice. In particular, mApoE-DOXO-LIPs were able to reduce the migration of GBM 
cells in the contralateral hemisphere and enhance the apoptosis of the tumor cells 
compared to DOXO-LIPs. 
A key point was the cotreatment of GSC-PDX with radiation together with mApoE-
DOXO-LIPs. The ability of radiation to temporarily open the BBB (Tamborini et al., 2016) 
proved a key factor in order to achieve mApoE-DOXO-LIP therapeutic accumulation and 
diffusion within the GBM tumor area, in particular in the peritumoral border where BBB 
maintain almost an intact structure and where the unresected GSCs lead to recurrence. 
Indeed, the highest efficacy on tumor regression and overall survival was obtained with 
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2Gy/mApoE-DOXO-LIPs cotreatment, suggesting the possibility to use mApoE-
functionalized LIPs as adjuvantof RT in GBM patients. 
An intriguing observation is the activation of the Iba1+ GAMM after the phagocytosis of 
tumor debris. Knowing that DOXO is a drug able to induce ICD in tumor cells (Kroemer et 
al., 2013, Kawano et al., 2016), GAMM change in morphology and consequently CD11c 
overexpression suggest that mApoE-DOXO-LIPs can induce ICD activation in GSCs that 
in turn activate GAMM as Antigen Presenting Cells (APC). The confirmation of this 
activation could represent a pivotal step further in immune system activation against GBM 
in a sort of in situ activation. However, the in vivo experiments conducted on GSCs 
transplanted in NOD/SCID mice represents a limitation in ICD activation by mApoE-
DOXO-LIPs. In particular, the absence of T cells forbid to verify the effective ability of 
GAMM to activate adaptive immune response. Therefore, it is essential to verify this 
mechanism in an immune fully competent in vivo model such as intracranial injection of 
mouse-derived glioma GL261 cell line in a synergic mouse. This would allow to follow not 
only the ICD activation in tumor cells but also to monitor the activation of the presenting 
cells and, finally, the activation of infiltrating T cells by antigen presentation. The proof of 
T cell activation by apoptotic GBM cells would represent a step forward to a possible 
mApoE-DOXO-LIPs translation to the clinic. Indeed, considering that all the components 
of this nanocarrier are already approved by FDA, the approval to the clinical use could be 
shorter than a new drug, giving a new possible therapeutic option as GBM immune 
therapy. 
Importantly, the use of DOXO as incapsulated drug represents an important achievement. 
DOXO is one of the most commonly used chemotherapeutic agent. It is known to display 
excellent antineoplastic activity in GBM cells in vitro but poor efficacy in vivo due to 
extrusion by multidrug resistance-related proteins present on both BBB and GBM cells 
(Haar et al., 2012). The conjugation of the mApoE peptide on liposomal DOXO 
formulations could efficiently overcome the impediments handed by the BBB, including 
drug resistance by molecular extrusion. Interestingly, mApoE confer a dual targeting 
system: on BBB and on GSCs. This aspect is essential to reduce the modification needed 
and enhance the efficacy. 
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Although significant tumor inhibition and increase overall survival, mApoE-DOXO-LIPs 
displayed a moderate, despite transient, systemic toxicity possible due to the tendency of 
nanovectors, mApoE-DOXO-LIPs included, to accumulate into the liver. Indeed, almost 
40% of the injected LIPs were found in the liver. 
This can constrain and make difficult the translation of mApoE-LIPs to the clinic. 
Therefore, different formulations were considered in order to obtain a drug delivery system 
more GBM-specific, efficient and safe. Different scaffold and functionalization were 
studied. LIPs were substitute with polymeric cores while mApoE targeting was replaced 
with a MMP2 activatable penetrating peptide. 
The polymeric NVs functionalized with MMP2 sensible CPP (ALMWP-DOXO-PCL) 
demonstrated to be extremely efficient to target GSCs derived from different GBM 
patients. Thanks to the high MMP2 synthesis by the GSCs, the ALMWP confer high 
specificity to tumor microenvironment without affecting healthy cells viability. ALMWP-
DOXO-PCL incubation with the endothelial cell line hCMEC/d3 demonstrated that in the 
proximity of a microenvironment with poor MMP2 activity the NVs remain inactivated 
and, consequently, it cannot target surrounding cells. 
Due to the presence of multi-functionalized terminal brushes, the star-shape architecture of 
the PCL NVs increase the possibility of interactions between targeting moiety/cell 
membrane and, consequently, NVs cellular internalization. Indeed, our results indicated 
ALMWP-DOXO-PCL are a more efficient GSC targeting NVs compared to mApoE-
DOXO-LIPs. The increased target efficacy is reflected by a higher cytotoxic effect. Indeed, 
ALMWP-DOXO-PCL exerted extremely GSC cytotoxicity at a DOXO concentration 
about ten-time lower compared to mApoE-DOXO-LIPs. 
This is a pivotal point of this thesis because the reduced DOXO amount required to obtain 
significant reduction of GSCs viability suggests the possibility that ALMWP-PCL could 
limit the undesired systemic side effect observed in LIPs. However, a more deep 
characterization is needed. 
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A more detailed direct comparison between liposome and PCL NVs is needed to 
definitively confirm that PCL NVs are more efficient as drug delivery compared to LIPs. 
Both uptake and cytotoxicity need to be confirmed in GSC derived from different patients. 
In particular, different DOXO concentration need to be tested to determine the exact 
minimal effective dose of both LIP and PCL. Moreover, the PCL NVs tested so far lack a 
functionalization that confer the BBB crossing ability. Therefore, a PCL NVs complete of 
activatable CPP and a functionalization that confers the BBB crossing ability, such as 
mApoE peptide already tested on LIPs, need to be tested both in vitro and in vivo. 
Conclusion 
In the last 15 years many attempts have been done to develop new drugs or to use 
molecules effective in other cancer treatment to treat GBM but all of them have failed. In 
this context, nanomedicine could have a pivotal role in GBM treatment efficacy, 
specifically targeting tumor cells and allowing drugs accumulation at the tumor site. The 
work of this thesis represents a step forward to demonstrate that drug-loaded targeted 
nanovectors can function as a delivery strategy to specifically and effectively drive 
chemotherapeutics into GBM tumor microenvironment and cells.  
mApoE-DOXO-LIPs demonstrated to be effective against GBM cells in vivo when 
coupled with RT, prolonging the mice overall survival, demonstrating that the 
encapsulation of a drug inside a NVs can enhance its efficacy against GBM thanks to the 
specific targeting of the tumor. Moreover, this data confirmed that chemotherapy need to 
be coupled with RT to be effective, working as an adjuvant agent likewise TMZ. In this 
way mApoE-DOXO-LIPs could be proposed as alternative adjuvant chemotherapy in a 
treatment protocol. 
Another important aspect is the use of DOXO as incapsulated drug against GBM. In a kind 
of drug repurposing, DOXO could be an “old-new” drug that could help to prolong GBM 
patient survival. In particular, DOXO ability to induce ICD activation after tumor cell 
death could be the cornerstone to elicit a stronger response against GBM guided by the 
immune system. This thesis demonstrated that nanomedicine could effectively play this 
role in drugs repurposing, giving new life to DOXO in GBM treatment. Finally, ICD 
  
80
activation confirms we need to improve our understanding in GBM microenvironment and 
how we can take advantage of it to obtain a stronger response against GBM and, why not, 
defeat it. 
In my opinion, the next years research in GBM treatment should focus on the development 
of more and more smart drug delivery systems able to cross the BBB and accumulate in the 
microenvironment of the GBM where directly target the tumor cells, especially the single 
GSCs disseminated at the tumor border, and able to remodulate the microenvironment 
component, specially the immune cells. In particular, this system should be able to induce a 
systemic response against the tumor to enhance the efficacy of the drugs and overcome the 




1. Synthesis and characterization of mApoE-DOXO-LIPs  
LIP composed of Sm/Chol/PE-PEG-mal (48.75:48.75:2.5 molar ratio) in ammonium 
sulphate (500 mM, pH 5.5) were prepared by extrusion procedure. LIPs (5 µmolstotal 
lipids) were incubated with 1 mg/ml DOXO for 1 h at 65°C to obtain DOXO-LIP. DOXO-
LIPs were then functionalized with mApoE (CWGLRKLRKRLLR-NH2, DBA Segrate, 
Italy) as described previously (Bana et a., 2014) to obtain mApoE-DOXO-LIPs. LIPs were 
purified by gel filtration (Sephadex G-25 fine resin). DOXO loading was quantified by 
measuring the DOXO fluorescence (λex = 495 nm; λem =592 nm) after liposomes 
disruption with 0.1% Triton X-100. Phospholipids content was quantified by Stewart 
Assay. The amount of mApoE attached on LIP surface was determined by measuring the 
shift of tryptophan fluorescence intensity (λex = 280 nm). Non-functionalized LIP and 
DOXO-LIP were used as controls. Stability was measured in PBS by following size and 
polydispersity index (PDI) by DLS for 10 days. The reported data are the mean of at least 
five different measurements. For transmission electron microscopic (TEM) evaluation, 
mApoE-DOXO-LIP were deposited on formvar and carbon coated 300 mesh copper grids 
(EMS, Hatfield—PA) and negatively stained with a solution of 2% Uranyl Acetate. After 
drying, the grids were examined under a Philips CM10 TEM (FEI, Eindhoven, NL) with 
an accelerating voltage of 80 kV and images were acquired with a Morada camera and 
iTEM software (Olympus, Tokyo, JP). Release of DOXO from loaded LIP was monitored 
at 37°C in phosphate buffered saline (PBS) at pH 7.4, 6.5 or 5.0. At various time points up 
to 14 days, an aliquot was withdrawn from LIP suspension and filtered using a 10 
kDaMWCO spin filter, at 4000 rpm. The filtrate, which contained DOXO released from 
the LIP, was analyzed for DOXO content as described above by spectrofluorimetry. DOX 
release was calculated using Eq. (1): 
DOXO release (%) = ([DOXO] filtrate / [DOXO] ini5al sample) * 100 




PLGA NVs. A solution of 19 mg of polymers (16.59 mg of PLGA-PEG and 2.41 mg of 
PLGA-PEG-Male, to obtain 10% of NPs surface with maleimide group) and 1 mL of 
acetone was dropwise into 1 mL of PBS (10mM pH 7.4) and stirred for 5 minutes (the 
solution became opaque). Then acetone was removed under reduced pressure (from 600 
mbar to 100 mbar in 30 minutes and then 1 hour at 100 mbar, at 37°C), obtaining 1 mL of 
PLGA-PEG-Male NPs suspension in PBS. 
T h e p e p t i d e s ( L M W P , C V S R R R R R R G G R R R R ; A L M W P , 
EEEEEEEEEEPLGLAGVSRRRRRRGGRRRRC (CASLO APS, Kongens Lyngby, 
Denmark) in PBS (0.1 eq. for each maleimide group, 290 µL for LMWP and 567 µL for 
ALMWP; from a 1 mg/mL stock solution) and tris(2-carboxyethyl)phosphine 
hydrochloride (TCEP) in PBS (0.5 eq. for each maleimide group; from a 6.58 mg/mL stock 
solution) were mixed in a vial for 5 minutes, then added dropwise in 1 mL of PLGA-PEG-
Male NPs suspension in PBS (19 mg/mL, 1 eq. of maleimide group). The reaction 
continued overnight under not vigorous stirring at room temperature. To remove TCEP, the 
solution was purified by ultrafiltration with Centrifugal Filters (MWCO 100 kDa, 
Amicon®) at 1500 rcf for 10 minutes, washing with 1 mL of PBS for 4 times to obtain 1 
mL of suspended NPs. 
Finally, 1.5 mg of Doxorubicin hydrochloride (DOXO-HCl) were dissolved in 1 mL of 
acetone with 0.71 µL of TEA. This solution was then added dropwise to the PLGA-PEG-
peptide NPs suspension (19 mg/mL) and stirred for 10 minutes. Acetone was then removed 
under reduced pressure (under controlled pressure gradient: from 600 mbar to 100 mbar in 
30 minutes and 1 hour at 100 mbar) at 32 °C. The free doxorubicin was removed by 
ultrafiltration with Centrifugal Filters (MWCO 100 kDa, Amicon®) at 1500 rcf for 10 
minutes, washing with 1 mL of PBS for 4 times, obtaining 1 mL of final NPs suspension 
(PLGA-PEG-LMWP DOXO-loaded NPs; PLGA-PEG-ALMWP DOXO-loaded NPs).  
3. Synthesis and characterization of star shaped, four arms PCL 
based nanovectors 
A solution of 19 mg of A4CL10PEG16-co-PCL4Acr dissolved in 1 mL of acetone were 
added dropwise into 1 mL of stirred PBS (10mM pH 7.4). After 5 minutes, acetone was 
removed under reduced pressure (under controlled gradient of pressure: from 600 mbar to 
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100 mbar in 30 minutes and then 1 hour at 100 mbar) at 32 °C, obtaining 1 mL of NPs 
suspension in PBS. 
The peptides in PBS (0.1 eq. for each acrylate group: 891 µL for LMWP, 1.74 mL for 
ALMWP, 782 µL for mApoE; from a 1 mg/mL stock solution) and Tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) in PBS (0.5 eq. for each acrylate group; 
from a 8.9 mg/mL stock solution) were mixed in a vial for 5 minutes, then added dropwise 
in 1 mL of A4CL10PEG16-co-PCL4Acrilated NPs suspension in PBS (19 mg/mL, 11.85 eq. 
of acrylate group). The reaction continued overnight under not vigorous stirring at room 
temperature. To remove TCEP, the solution was purified by ultrafiltration with Centrifugal 
Filters (MWCO 10 kDa, Amicon®) at 1500-2000 rcf for 10 minutes, washing with 1 mL of 
PBS for 4 times to obtain 1 mL of suspended NPs. 
Finally, 1.5 mg of Doxorubicin hydrochloride (DOXO-HCl) were dissolved in 1 mL of 
acetone with 0.71 µL of TEA. This solution was then added dropwise to the NPs 
suspension (19 mg/mL) and stirred for 10 minutes. Acetone was then removed under 
reduced pressure (under controlled gradient of pressure: from 600 mbar to 100 mbar in 30 
minutes and 1 hour at 100 mbar) at 32 °C. The free doxorubicin was removed by 
ultrafiltration with Centrifugal Filters (MWCO 10 kDa, Amicon®) at 1500-2000 rcf for 10 
minutes, washing with 1 mL of PBS for 4 times to obtain 1 mL of final NPs suspended 
(A4CL10PEG16-co-PCL4-LMWP DOXO-loaded NPs; A4CL10PEG16-co-PCL4-ALMWP 
DOXO-loaded NPs; A4CL10PEG16-co-PCL4-mApoE DOXO-loaded NPs). 
4. Patient-derived GSC primary cell culture establishment 
Patient-derived Glioma stem cell (GSC) primary cultures were obtained from GBM 
surgical samples of patients undergoing surgery for brain tumor removal. Surgical 
specimens were collected from consenting patients in the Department of Neurosurgery at 
Humanitas Research Hospital (Rozzano, Italy) and Neurological Institute “C. Besta” 
(Milan, Italy) under “Humanitas” and “C. Besta” research ethics committee approval. 
Tumor samples were processed as by Gritti et al. (Gritti et al., 1996). Briefly, resection 
specimens received from neurosurgical unit of Humanitas Hospital were quickly dissected 
with scalpels and incubated with collagenase and DNAse. After 20 min incubation at 37°C, 
cell suspension were centrifuged and the pellet incubated with dH2O in order to eliminate 
erythrocytes. Finally, after dH2O rebalance with 10X PBS, cell suspension was filtered 
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through a 40µm strainer and incubated in fresh medium. Brain tumor-derived neurospheres 
were evident as early as 1 week after plating (Fig. 30 A). Spheres were grown for at least 3 
weeks or until they reached a size adequate for plating and passaging (~200 µm).  
Six different GSC lines were used in this project. All GSCs were tested for stemness by 
Extreme Limiting Dilution Analysis (ELDA) as described by Hu and Smyth (Hu, Y, and 
Smyth, GK, 2009). GSCs were plated at a concentration of 1, 2, 5, 10 or 40 cells per well 
in a 96 wells plate. The frequency of cells able to renew tumor spheres was determined 
after two weeks of culture by counting the number of spheres generated per single well. All 
the GSCs demonstrated a high renewing capacity: in ICH001 renewed 1 cell every 1,4; in 
ICH003 1 every 2,32; in ICH013 1 every 2,90; in BG003 1 every 3,74; in BG005 1 every 
5,22; in GBM3 1 every 4,22. 
The expression of the “stemness” markers CD133 and SOX2 were evaluated by real-time 
PCR in the GSC cultures and the differentiated human astrocyte (SVG cell line) (Fig. 30 
B). 
Pro-neural (PN) and Mesenchymal (MES) GSCs subtype (Bath et al., 2013; Halliday et al., 
2014; Moreno et al., 2017; Rooj et al., 2017; Minata et al., 2019) were determined by gene 
profiling using the selected PN genes CD133, SOX2, SOX9, OLIG2, ADGRG1, and MES 
genes CD44, CTGF, FN1, CHI3L1, ALDH1A3. BG003 and BG005 displayed a PN 
profile. ICH001, ICH003 and GBM3 had a mixed PN/MES phenotype and could be 
classified as “classical” GSC lines. ICH013 showed a MES profile (Fig. 30 C). 
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A) Schematic representation of patient derived GSCs line preparation. After surgical resection, GBM tissue is mechanically dissected into tiny pieces that 
undergo enzymatic digestion to obtain single cells suspension. This suspension is then plated in culture medium until cell line is stabilized and ready to be 
used. B) Gene expression analysis of  the stem marker CD133 and C) SOX2 in the selected GSCs compared to the differentiated human fetal glial cell line 
SVG. D) Gene expression analysis on selected genes to determine pro neural (PN) or mesenchymal (Mes) profile of ICH001, ICH003 and ICH013. 
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Fig. 30: patient-derived GSC primary culture establishment and characterization. A) Schematic representation of 
patient derived GSCs line preparation. After surgical resection, GBM tissue is mechanically dissected into tiny pieces that 
undergo enzymatic digestion to obtain single cells suspension. This suspension is then plated in culture medium until cell 
line is stabilized and ready to be used. B) Gene expression analysis of  the stem marker CD133 and SOX2 in the 
indicated GSCs and in the differentiated human glial cells (SVG cell lines). C) PN/MES gene profiling by real-time PCR. 
Pairwise comparison was performed by Student’s t-test: *p < 0.05. 
5. In vitro transwell BBB model  
hCMEC/D3 cells (7×104 cells/cm2, passages 25-35) were seeded on 12-well transwell 
inserts coated with type I collagen and cultured with 0.5 ml or 1 ml of culture medium in 
the upper and in the lower chamber. hCMEC/D3 monolayers integrity was verified by 
measuring the endothelial permeability (EP) of [14C]-sucrose and [3H]-propranolol and 
the transendothelial electrical resistance (TEER) (measured by EVOMX meter, STX2 
electrode; World Precision Instruments). For permeability experiments, after 3 h of 
incubation with 2.5 or 25 µg/ml of DOXO, free or embedded into LIPs, the amount of 
DOXO in the basolateral compartment was measured by fluorescence and the EP to 
DOXO calculated as described (Ceccherelli et al., 1999). LIP integrity after BBB crossing 
was evaluated by Nanoparticle Tracking Analysis (NanoSight NS300, Malvern 
Panalytical). Impact of free-DOXO or DOXO-LIPs on cell monolayers was checked by 
measuring TEER and EP of Lucifer Yellow (50 µM) after hCMEC/D3 incubation. For 
cytotoxicity experiments, hCMEC/D3 were co-culture with U87-MG, A172 cells (5.4x104 
cells/well) adherent to the bottom of the basolateral compartment. 25 µg/ml of DOXO, free 
or embedded in LIP, were added to apical compartment and incubated for 3h. Then, upper 
inserts were removed and GBM cells cultured for additional 48h in the lower chambers. 
Viability was evaluated by MTT assay. 
6. In vitro viability assay  
GSCs (104 cells/well) or endothelial hCMEC/D3 cells (5 103 cells/well) were plated in 96-
well plates in a final volume of 200 µl of medium in the absence/presence of increasing 
doses of different NVs at the indicated doses of DOXO. Only in the experiments using the 
GBM integrated BBB model, LIPs were removed 3h after treatment. 24-48-72h after 
treatment depending on experimental design, the mitochondrial enzymatic activity, index 
an indicator of cell viability, was assessed by MTT assay. Briefly, 4h before the end of the 
treatment, 20 µl of MTT were added directly in each well to a final concentration of 0,5 
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mg/ml. At the finish of the treatment, plate were centrifuged at 1500 rpm for 15 min to 
pellet down the cells. Surnatnat was removed and 100 µl of DMSO were added in each 
well to solubilized the formazan salt crystals. After 15 min shaking at room temperature, 
absorbance was red at 570 and 630 nm. Final absorbance values were determined 
subtracting 630 nm value to the corresponding 570 nm. 
7. Nuclear DOXO quantification by confocal microscopy 
GBM cells (U87-MG, A172 and T98G), GSCs and hCMEC/d3 endothelial cells were 
seeded on glass coverslips at a concentration of 3500 cell/cm2. The day after the cells were 
incubated at different condition: free DOXO, DOXO-LIP or mApoE-DOXO-LIP at 
[DOXO] of 4 µg/ml for 4h; DOXO-PCL, LMWP-DOXO-PCL or ALMWP-DOXO-PCL 
[DOXO] of 1,2 µg/ml for 6h. In the experiments with the endocytosis inhibitors, 
Chlorpromazine (10 µM) or Dynasore (80 µM) were added to the cell medium one hour 
before the cell incubation with the liposomes. The inhibitors were kept into the cell 
medium during the whole experiment (5 hours’ incubation). Irradiated GSCs were 
incubated with LIPs 20h after radiation treatment. Cells were irradiated with a single dose 
of 2 Gy using an X-ray biological irradiator operating at 12 mA/190kV (RADGIL, 
Gilardoni, Lecco, Italy) at a dose rate of 0.65 Gy/min. Cells were fixed in PFA 4% in PBS 
for 15 min, DAPI (Sigma-Aldrich) stained (10 µg/ml in PBS, 30 min) and mounted in 90% 
glycerol in PBS. The Z-stack series of the cells in different experimental conditions were 
acquired by means of a confocal microscope (TCS SP5, Leica Microsystems GmbH) with 
the HCX PL APO 63x/1.4 OIL objective. The DAPI (Ex/Em: 405/415-450 nm), Syto45 
(Ex/Em: 458/470-500 nm) and DOXO autofluorescence (488/570-700) signals were 
acquired sequentially at high scan rate. Images were processed using Fiji (Schindelin et al., 
2012) using the DAPI signal to segment the nucleus. The DOXO fluorescence was 
quantified in the nuclei as mean grey values in the optical section were the nucleus area 
were maximized.  
8. Nuclear DOXO quantification by live imaging microscopy 
GSCs were seeded in a 96 well “flat bottom” pre-coated (5µg/ml collagene, 1µg/ml 
fibronectin) plate at a concentration of 15625 cells/cm2. After 24h, cell’s were treated with 
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PLGA-PEG NVs (PLGA-PEG-DOXO, PLGA-PEG-LMWP-DOXO or PLGA-PEG-
ALMWP-DOXO, [DOXO] 4 µg/ml in every condition) or PCL-PEG NVs (PCL-PEG-
DOXO, PCL-PEG-LMWP-DOXO or PCL-PEG-ALMWP-DOXO, [DOXO] 1,2 µg/ml in 
every condition) up to 10 h. Nuclear DOXO accumulation was monitored once per hour in 
each well (4 repetition per each treatments per GSCs) by DMi8 fluorescent microscopy 
and LasX software (Leica Microsystems GmbH). The DAPI (Ex/Em: 405/415-450 nm) 
and DOXO autofluorescence (488/570-700) signals were acquired sequentially at 20X 
magnification. Images were processed using Fiji using the DAPI signal to determinate 
nucleus area. The DOXO fluorescence was quantified as mean grey values in the nucleus 
area. 
9. Immunocytochemistry 
LDLR level of expression in GSC cultures was detected by immunostaining incubating the 
cells (5x104 cells on 18mm coverslips) with primary antibody against human LDLR 
(1:100, Sigma-Aldrich) over night at 4°C. After primary antibody, samples were incubated 
with anti-mouse secondary antibody conjugated with Alexa Fluor® 488 (1:200, Thermo 
Fisher, Waltham, Mas) and anti-Phalloidin conjugated with Alexa Fluor® 647 (1:200, 
Thermo Fisher, Waltham, Mas) for 1h at room temperature. Glasses were mounted with a 
PBS/glycerol mixture (1:1) with DAPI (1:40.000) (Sigma-Aldrich, St. Louis, MO). LDLR 
level of expression was quantified by confocal images processed using Fiji software and 
the “Analyze Particles” tool.  The central, upper, and lower sections of 1µm z-stack were 
analyzed for each image and the LDLR threshold, determined on the negative control, was 
kept constant in each of the experimental conditions. LDLR level was calculated as LDLR-
positive fluorescent area normalized to the cellular cytoplasmatic area demarcated by the 
Phalloidin staining. 
10. MMP2 protein level and enzymatic activity 
MMP2 protein level was determined by Western Blot analysis on 4*106 GSC cells 
incubated 24h  in 4 ml of fresh complete culture medium. 1:1000 ab α-MMP2 (Sigma-
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Aldrich, St. Louis, Mis) was incubated overnight at 4°C. 1:5000 secondary ab (Thermo 
Fisher, Waltham, Mas) was incubated 1h at room temperature. The signal intensity was 
determined by ChemiDoc Imaging System (BioRad, Hercules, CA) and analyzed by Image 
Lab software (BioRad, Hercules, CA). Samples were normalized on protein total amount. 
MMP2 activity was determined by zymography as described in Frankowski et al. 
(Frankowski et al., 2012). Briefly, 5µl of medium conditioned by cells employed for 
Western Blot were mixed with 15 µl of Zymogram Sample Buffer (BioRad, Hercules, CA) 
and loaded in a 8% polyacrylamide gel supplemented with 0,1% gelatin B (MMP2 
substrate). After 2h running at 90 V voltage for 2h, gel was washed 3 times with 
Zymogram Renaturation Buffer (BioRad, Hercules, CA). Then, gel was incubated with 
Zymogram Development Buffer (BioRad, Hercules, CA) for 1h at room temperature. After 
changing Development buffer with fresh one, gel was incubated at 37°C for at least 12h. 
Finally, gel was incubated with Safe Comassie (BioRad, Hercules, CA) for 2h and 
destained in dH2O until the desired blue coloring. The digestion intensity was determined 
by ChemiDoc Imaging System (BioRad, Hercules, CA) and analyzed by Image Lab 
software (BioRad, Hercules, CA). 
11. mApoE-DOXO-LIP biodistribution 
All procedures involving animals were conducted according to Italian laws and the Animal 
Utilization Protocols approved by the Italian Ministry of Health. 6–8 weeks old male Balb/
c mice (3 mice/group; Charles-River Laboratories) were injected via the tail vein with 100 
µL of radiolabelled mApoE-DOXO-LIP (10mM total lipids, 5 mg/kg DOXO, 0.5 µCi/
mouse [3H]-Sm, 0.3 µCi/mouse [14C]-DOXO) or free DOXO (5 mg/kg, 0.3 µCi/mouse 
[14C]-DOXO) in PBS. After mice were sacrificed a total of 0.1 g of each tissue or 100 µl 
of blood, in triplicate, were solubilized at 55◦C for 2h and cooled to room temperature. 
Radioactivity was measured by liquid scintillation counting. Data were expressed as 
percentage of injected dose on total organ weight/volume ± SD. The possible radioactivity 
derived from the blood was subtracted from the radioactivity values measured in the brain 
(-5% of measured radioactivity). 
12. GSC orthotopic xenografts and treatments  
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To study mApoE-DOXO-LIP antitumor activity, luciferase transfected GSC1luc cells (4 × 
104) were stereotactically injected into the right striatum of 4-week-old male NOD/SCID 
mice (NOD.CB-17-Prkdcscid/J, Charles-River). Luciferase stable expression was obtained 
using the pRRL.sin.PPT.CMV.Luciferase.iresEMCVwt.eGFP.pre lentiviral vector 
engineered by Dr E.Vigna and kindly provided by Dr. C.Boccaccio (Candiolo Cancer 
Institute, Candiolo, Torino, Italy) (De Bacco et al., 2016). From 6 weeks after intracranial 
inoculation, tumors were monitored by BLI imaging (IVIS® II Imaging, Caliper Life 
Sciences-PerkinElmer) once a week. Treatments started at 8 weeks after tumor injection 
(D60) when tumors were detectable by BLI. In order to obtain comparable results, animals 
were randomized according to BLI imagines into groups homogeneous for tumor 
dimension. All treated mice received 35 µg/dose/mouse of DOXO delivered by DOXO-
LIPs or mApoE-DOXO-LIPs administered intraperitoneal. Whole-brain radiation (2Gy) 
was performed using an X-ray irradiator operating at 12 mA/190kV (RADGIL, Gilardoni). 
mApoE-DOXO-LIPs were administered 16-18h after radiation.  
13. Histopathology analysis and TUNEL assay 
Animals were euthanized with intracardiac perfusion of saline solution, followed by 4% 
paraformaldehyde fixation. Harvested brains were frozen, and serial cryosections (10m 
thick) were prepared and stored at -80C°. Three coronal sections (one at the intersection of 
the tumor injection site plus one anterior and one posterior sections at 50 m distance, were 
analyzed for each single treated and untreated mouse.  
Frozen brain sections were immunostained with mouse anti-Human Nuclei (clone 235-1, 
Sigma), rabbit anti-Iba1 (Wako) primary antibodies followed by anti-mouse Alexa Fluor 
488 and anti-rabbit Alexa Fluor 555 secondary antibodies (Thermo Fisher, Waltham, Mas). 
The Click-iT Plus Alexa Fluor 647 TUNEL Assay (Thermo Fisher, Waltham, Mas) was 
used to detect in situ apoptosis and DAPI for nuclei staining. Coronal images were 
acquired using a DMi8 fluorescent microscope and Leica Application Suite X (LAS X) 
imaging system (Leica Microsystems). Confocal microscopy was performed using a Leica 
TCS SP8 confocal microscope. Maximum projections were obtained from 29-35 Z-stacks. 




14. Statistical analysis 
In vitro data are expressed as mean values ± standard deviation (SD) or standard error (SE) 
of at least three independent experiments performed in replicates. Student’s t-test was used 
for pairwise comparison. Significance was defined at P < 0.05. In vivo statistical 
significance among treatments was evaluated by ANOVA using correction post hoc tests 
(Bonferroni or Turkey’s multiple comparisons as indicated). Statistical analyses were 
performed using Prism 8 (GraphPad Software).  
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IL-1β Interleukin 1β 
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